

Systematic review of the prevalence of Long Covid

Mirembe Woodrow, Charles Carey, Nida Ziauddeen, Rebecca Thomas, Athena Akrami, Vittoria Lutje, Darren C Greenwood*, Nisreen A Alwan*

School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK (M Woodrow MSc, N Ziauddeen PhD, NA Alwan PhD); Manchester University NHS Foundation Trust and The University of Manchester, Manchester, UK (C Carey MBChB); NIHR Applied Research Collaboration Wessex, Southampton, UK (N Ziauddeen PhD, NA Alwan PhD); University of Liverpool, Liverpool, UK (R Thomas MBChB, MPH); Sainsbury Wellcome Centre, University College London, London, UK (A Akrami PhD); Patient-led Research Collaborative, Washington DC, USA (A Akrami PhD); Cochrane Infectious Diseases Group, Liverpool, UK (V Lutje DVM, PhD); School of Medicine, University of Leeds, UK (DC Greenwood PhD); NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK (NA Alwan PhD)

*Equal contribution as senior authors

Correspondence to: Prof Nisreen A Alwan, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK

ORCID iD: 0000-0002-4134-8463

Email: n.a.alwan@soton.ac.uk

Summary (300 words)

Background:

Long Covid occurs in those infected with SARSCoV2 whose symptoms persist or develop beyond the acute phase. We conducted a systematic review to determine the prevalence of persistent symptoms, functional disability or pathological changes in adults or children at least 12 weeks post-infection.

Methods: We searched MEDLINE (Ovid), Embase (OVID), the Cochrane Covid-19 Study register, WHO ICTRP, medRxiv, Cochrane CENTRAL, MEDLINE (PubMed), ClinicalTrials.gov, and the WHO Global research on coronavirus disease (COVID-19) database from 1st January 2020 to 2nd November 2021, limited to publications in English. We included studies with at least 100 participants. Studies where all participants were critically ill were excluded. Articles were screened independently by two reviewers, with disagreements resolved by a third. Long Covid (primary outcome) was extracted as prevalence of at least one symptom or pathology, or prevalence of the most common symptom or pathology, at 12 weeks or later. Heterogeneity was quantified in absolute terms and as a proportion of total variation and explored across pre-defined subgroups (PROSPERO ID CRD42020218351).

Findings: In total 120 studies in 130 publications were included. Length of follow-up varied from 12 weeks to over 12 months. Few studies had low risk of bias. All complete and subgroup analyses except one had $I^2 \geq 90\%$, with prevalence of persistent symptoms ranging between 0% and 93%. Studies using routine healthcare records tended to report lower prevalence of persistent symptoms/pathology than self-report. However, studies systematically investigating pathology in all participants at follow up tended to report the highest estimates of all three. Studies of hospitalised cases had generally higher estimates than community-based studies.

Interpretation: The way in which Long Covid is defined and measured affects prevalence estimation. Given the widespread nature of SARSCoV2 infection globally, the burden of chronic illness is likely to be substantial even using the most conservative estimates.

Funding: this systematic review received no specific funding.

Panel: Research in context

Evidence before this study

The chronic effects of COVID19 were accounted for in relation to the health, social and economic impacts at the start of the pandemic in 2020. Long Covid is now established as a serious outcome of infection with SARSCoV2 that influences the daily lives of many. To estimate the population-level burden, the prevalence of prolonged health effects from SARSCoV2 infection needs to be quantified. We conducted a systematic review of published studies to determine the prevalence of persistent symptoms, functional disability or pathological changes in adults or children at least 12 weeks post-infection.

Added value of this study

We included 120 studies assessing Long Covid symptoms, functional status, or pathology published up to November 2021. There was significant heterogeneity between studies and wide variation in Long Covid prevalence estimates ranging between 0-93%. This is due to differences in Long Covid definition, required threshold of severity or impact on daily activities, study designs, sources of study samples, how the initial infection was defined, number of assessed symptoms and method of assessment. Despite large between-study heterogeneity, the studies with lowest risk of bias estimated prevalence between 3% and 37%. For studies that included comparison of cases to controls, there were significant methodological considerations to the choice of control groups including difficulty ascertaining the absence of exposure (SARSCoV2 infection). The review search timeline meant Long Covid prevalence in vaccinated populations could not be assessed.

Implication of all the available evidence

Even with the most conservative estimates of prevalence among those infected, the chronic disease burden generated by SARSCoV2 infection seems substantial, particularly in countries where community transmission of SARSCoV2 is high.

Introduction

Long Covid is the state of not fully recovering for many weeks, months or years after contracting SARSCoV2 infection. The World Health Organization (WHO) defines Post COVID-19 Condition (Long Covid) as the condition occurring in individuals with a history of probable or confirmed SARSCoV2 infection 3 months after the onset with symptoms that last at least 2 months, cannot be explained by an alternative diagnosis and generally impacts everyday functioning(1). These symptoms may be the same as the acute illness or new symptoms developing weeks or months after the acute phase. Clinical guidelines(2, 3) in the UK and the US consider Long Covid as symptoms ongoing for four weeks or more.

Long Covid can occur across the spectrum of severity of initial infection(4). A wide range of symptoms have been reported with exhaustion, breathlessness, muscle aches, cognitive dysfunction, headache, palpitations, dizziness and chest tightness or heaviness amongst the most common(5, 6). Patients are still struggling to access adequate recognition, support, medical assessment and treatment(7, 8). The prevalence of Long Covid remains uncertain as it is dependent on the case definition used and the duration of follow-up.

Studies assessing the prevalence of Long Covid have produced wide-ranging results due to varying settings, case definitions, population denominators and methods of ascertainment. For the purposes of this review, we define Long Covid as persistent (constant, fluctuating or relapsing) symptoms and/or functional disability and/or the development of new pathology following SARSCoV2 infection for equal or more than 12 weeks from onset of symptoms or from time of diagnosis, in people where the infection is self-described, clinically diagnosed, and/or diagnosed through a laboratory test.

We aimed to systematically collate, appraise and synthesise studies that describe the prevalence of Long Covid and to characterise its typology including patient demographics, symptoms/function disability and pathology. The review question was: What is the prevalence of prolonged symptoms and/or new functional disability and/or new pathology following SARSCoV2 infection among all people infected?

Methods

Search strategy and selection criteria

This is a systematic review and meta-analysis of the prevalence of prolonged symptoms following SARSCoV2 infection. Included study designs were cohort (retrospective and prospective), cross-sectional and case control studies with an estimate of the denominator (to calculate prevalence). These include community studies of whole populations; outpatients, institutionalised groups such as schools or military, or hospitalised patients; and support groups or patient panels. Studies were restricted to those published in English between 1st January 2020 and 2nd November 2021. There were no restrictions on publication type with peer-reviewed articles, online reports, letters and preprints included.

Only studies with a sample size of 100 or more participants (at the time of follow-up assessment if longitudinal study) were included. A sample of 50 or more per subgroup was required for subgroup analysis. Studies were included if participants were followed-up/assessed at a minimum of 12 weeks post-infection.

Studies of adults and children with a confirmed or probable SARSCoV2 infection in any age group (as defined by each study) were included. The control group in studies that included one was individuals with a confirmed or probable case of SARSCoV2 infection (as defined by the study) without

prolonged symptoms or pathology who have completely recovered (duration as defined by study as long as under 12 weeks from symptom onset or confirmation of infection) and have no new pathology attributed to SARSCoV2 infection. Studies that compared population-based prevalence, for example previously established national estimates, as the control arm were excluded from the control analysis but not from the case analysis.

This review is primarily concerned with general population estimates, but community-based, hospital-based, and mixed studies were all included, apart from studies that only reported outcomes for critically ill patients admitted to intensive care, because this review did not aim to estimate delayed recovery following ICU admission (post-ICU syndrome). Patients who were not hospitalised within two weeks of symptom onset but were subsequently hospitalised were counted as non-hospitalised for the purpose of this review.

A systematic search was conducted using MEDLINE (Ovid), Embase (Ovid), the Cochrane Covid-19 Study register (www.covid-19.cochrane.org; includes Cochrane Central Register of Controlled Trials (CENTRAL), WHO International Clinical Trials Registry Platform (ICTRP), medRxiv, Cochrane CENTRAL, MEDLINE (PubMed), ClinicalTrials.gov, and the WHO Global research on coronavirus disease (COVID-19) database(9). The initial search was run on 13 November 2020 and updated on 2 November 2021, both by VL. An example of the search strategy applied to Medline is provided in the Supplementary material; it was adapted for other databases as needed.

The screening management software Covidence was used to screen titles for eligibility. All articles were screened independently by two reviewers at each stage (title, abstract, and full text) with any discrepancies resolved by NAA. This review is reported in line with PRISMA guidelines(10). The protocol for this review was published on the international prospective register of international reviews, PROSPERO (CRD42020218351): https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=218351.

Data analysis

Data for each study was extracted independently by two of four reviewers (MW, DCG, CC, NZ). Any discrepancies were resolved by consensus between the two reviewers for each study or by a third reviewer (NAA).

Where multiple publications were identified as originating from the same study, all data was extracted but each data point was only used once in the analysis. In addition to excluding duplicate reports, or duplicate results from the same study, a number of general decisions were made to cope with multiple publications from the same study, either focusing on different lengths of follow-up, different timepoints, or different subgroups. These were guided by principles of (1) avoiding double counting individuals, (2) using the most appropriate outcome, for example, general Long Covid definition, in the broadest group such as the widest population, largest sample, most recent update, (3) unless stratifying by length of follow-up, we took the earliest and/or most complete follow-up as the main result.

The primary outcome is Long Covid, defined as non-recovery from COVID-19, according to symptoms, functional ability or pathology. SARSCoV2 infection can be confirmed, probable or suspected with prolonged symptoms (including but not limited to those explicitly defined as 'new onset'), functional disability or pathology for equal to or more than 12 weeks from onset of symptoms or positive test date (as defined by the study).

The measure of effect was the probability of not recovering within all SARSCoV2 infections or those initially symptomatic COVID-19 infected people included in each study. Secondary outcomes

included the demographics of people with Long Covid in relation to each study's denominator, prevalence of specific persistent or relapsing symptoms, prevalence of functional disability, and the characterisation of post-COVID-19 pathology.

Risk of bias was assessed as part of the data extraction process. A Long Covid-specific risk of bias tool was developed, based on the Newcastle-Ottawa scale, but tailored to the relevant sources of bias. The domains used are reported in Table 1. Risk of bias was particularly assessed in relation to the denominator, how the symptoms were assessed (active or passive elicitation of the symptoms) and hospital stay. Subgroup analysis by risk of bias was performed.

Data extracted included study details, setting, design, sample size, numerator and denominator criteria, all patient/participant reported characteristics including demographic, socioeconomic, clinical (including comorbidities, investigations, treatments) and functional characteristics, outcomes, information for assessment of risk of bias, reported conflicts of interest, ethical approval and any other important limitations. In studies where follow-up was measured post-hospital admission or discharge, symptom onset was estimated to have been 7 or 14 days prior to discharge respectively and estimated as 21 days if follow-up was measured from a post-infection negative test.

The prevalence was extracted as cumulative incidence. In extracting the prevalence of persistent symptoms, we used either prevalence of at least one symptom or pathology, or the prevalence of the most common symptom/pathology, depending on the data reported by the study. Data for each symptom was extracted separately in studies that reported on the prevalence of individual symptoms but did not provide an overall estimate of prevalence of Long Covid. We used the symptom with the highest estimate as our best estimate of overall prevalence, though it is likely to be an underestimate of actual prevalence. In studies with controls, the prevalence of the same symptom was used for comparison. In extracting controls data, our preference was for test-negative controls but we also extracted population untested controls. Where length of follow-up varied between study participants, we report a measure of average (e.g. mean or median) length of follow-up, or the midpoint of the reported range.

The heterogeneity was quantified both in absolute terms (range of individual study estimates) and as a proportion of total variation (I^2), and explored across pre-defined subgroups described below. Pooled prevalence estimates were not reported in meta-analyses if I^2 was above 75%. Heterogeneity was explored by stratifying on pre-defined subgroups: outcome type (pathology, symptom, functional status), geographical region (China, Europe, North America, Mixed and other), source of sample (community, healthcare workers, outpatients, hospital inpatients), length of follow-up, study design, confirmed diagnosis, and other risk of bias domains. We also stratified by severity score based on the WHO Clinical Progression Scale [supplemental methods]. We specified in the protocol that we would analyse these predefined subgroups regardless of heterogeneity.

All analysis was conducted in Stata version 17(11). The distribution, prevalence estimates, numerators, denominators, and assessment time points in different populations was qualitatively summarised. We used random-effects meta-analysis on the logit of the proportions to ensure estimates and confidence limits did not go below 0% or over 100%, transforming back to the original scale for presentation. Potential small study effects such as publication bias were investigated using contour-enhanced funnel plots and Egger's test of funnel plot asymmetry.

Role of funding source

There was no specific funding source for this study.

Results

Literature search

The searches found 11,518 studies in total. After deduplication and title and abstract screening, 457 full text studies were assessed for eligibility. Hand-searching sourced an additional 9 studies and in total 130 publications were included, 120 of which were discrete studies (Figure 1). 24 studies were conducted in China (including Hong Kong), 66 in Europe, 14 in North America and 16 in various other countries(12-141). Reasons for exclusion are listed in Supplementary Table 1.

Table 2 summarises the included studies' key characteristics and primary outcome for the first follow-up. Study design was reported as described by each study or designated based on study description if not explicitly stated. Most studies were in adults and included patients who were hospitalised in the acute phase (24 studies with <10% of the sample hospitalised in the acute phase). However, hospitalisation did not always correspond with disease severity, probably due to local diagnostic, treatment, and containment policies.

Most studies explicitly aimed to describe persistent COVID-19 symptoms or pathology and their prevalence. A minority had other aims, for example, describing the immune response, but their results included prevalence data. Some studies looked only at specific groups of symptoms, for example, olfactory or cognitive. Few studies included an indicator of the severity of symptoms/pathology. Most studies used PCR testing to identify COVID-19 cases at baseline. However most did not perform COVID-19 diagnostic tests at follow-up and therefore did not consider the impact of reinfection on their results. Besides studies in hospitalised settings and out of the included studies, 21 were community-based studies, 17 were in outpatient settings, 3 recruited through social media and 8 were healthcare worker-based studies.

Prevalence estimates

The prevalence of Long Covid for studies with more than 12 weeks from infection at first study follow-up ranged between 0% to 93% (Figure 2). 73 included analyses had a follow up of 12 weeks to 5 months, 49 had a follow-up of 6-11 months and 12 had a follow-up of 12 months or more. The range of prevalence in studies with follow-up of 12 months or more was 17% to 77% (Supplementary Figure 1). For all complete and subgroup analyses except one, I^2 was >75%. Therefore, pooled prevalence estimates, except for one, are not presented.

The prevalence range in analyses where less than 10% of the participants were hospitalised was 0% to 67% (n=24). In studies where all participants were hospitalised for acute COVID-19 (n=65), the prevalence range was 5% to 93% (Supplementary Figure 2). Out of all included analyses, 31 had 10% or more of their sample admitted to intensive care unit (ICU) during their acute COVID-19 illness (Supplementary figure 3). Studies including more hospitalised participants or more patients in ICU tended to report higher prevalence estimates. Likewise using the WHO CPS, studies including those with ambulatory mild disease (n=38) generally reported lower prevalence estimates than those with hospitalised severe disease who needed oxygen by NIV or high flow (n=27) (0-67% vs 9-93%) (Supplementary Figure 4).

The prevalence of not returning to full health/fitness after at least 12 weeks from infection ranged between 8% to 70% (n=10) (Supplementary Figure 5). The prevalence of lower quality of life was 31% (n=2) (Supplementary Figure 6). With regards to individual symptoms, common symptoms reported included fatigue followed by breathing problems, sleep problems, tingling or itching, and joint/muscle aches and pains. With regards to pathology, lung pathology was the most common followed by heart or neurological pathology (Supplementary Figures 7-40).

Risk of bias in each study is summarised in Supplementary Table 2. There were very few studies with a low risk of bias. Only five studies scored 9 out of 10 domains with a prevalence range of 3-37%. There was evidence of high-quality systematic assessment of participants in most studies, but few studies used a sample that was representative of all COVID-19 cases in the population. Few also considered the differential effects of interventions and treatments. Approximately half of the studies indicated that symptoms had not been present prior to infection, while the rest have not reported ascertaining this.

When stratifying by risk of bias, generally lower prevalence estimates were seen in studies with COVID-19 diagnoses confirmed for all participants, studies scored as having a representative sample, studies with an internal or external non-COVID-19 comparator, studies that assessed all participants in the same way, and studies based on community participants (non-hospitalised during the acute phase of their COVID-19 illness) (Supplementary Figure 41-42).

Comorbidities, ethnicity and other demographic data were not reported in all studies. Supplementary Figure 43 presents a summary of studies by risk factors and comorbidities, indicating higher prevalence of persistent symptoms in studies where populations had higher proportions of older people, males, people of non-white ethnicity, diabetes, hypertension, cardiovascular disease, and related comorbidities.

Prevalence estimates derived from assessing Long Covid as self-reported symptoms and function (n=93) on the whole tended to report higher prevalence than those that used clinical coding in healthcare records (n=7). However, studies that had dedicated pathology follow-up of COVID-19 patients (for example pulmonary function tests or scans with pathology discovered at follow-up) tended to report the highest prevalence (n=20) (Figure 3). Studies that defined Long Covid as at least one of multiple symptom or pathology domains on the whole tended to report a higher prevalence than those that assessed a single symptom/pathology domain (Supplementary Figure 44).

Comparison to controls

Twenty-four of the 130 publications included comparison to at least one group of controls (26 comparisons, Supplementary Figure 45), out of these 12 community study estimates were included in the analyses. The majority of studies used test-negative controls (antigen and antibody, with some matching), but others used untested controls.

In community-based studies with controls, the relative risk ranged between 1.0 to 51.4 and the absolute risk difference ranged between -1% to 35% (Supplementary Figures 46-47). In community-based samples with controls and assessed as having a low risk of bias (n=4), the pooled relative risk of experiencing symptoms/ill health after COVID-19 was 1.33 compared to controls (95% CI 1.31, 1.34 $I^2=28%$) (Figure 4) and the absolute risk difference between cases and controls ranged between 1% to 9% (Supplementary Figure 48).

There was no evidence of small-study effects such as publication bias (Supplementary Figure 49).

Discussion

This systematic review which included 120 studies assessing Long Covid symptoms, functional status, or pathology published up to November 2021 demonstrates significant heterogeneity between studies and wide variation in prevalence estimates. This is due to differences in study designs (cross sectional or longitudinal), sources of study samples (community, outpatient clinic, occupational, hospitalised) and number of assessed symptoms and method of assessment (self-reported individual or collective symptoms, healthcare records, clinical investigations at follow up).

The only pooled estimate with sufficiently low between-study heterogeneity to report was a 33% (95% CI 31-34) excess risk of experiencing prolonged symptoms in COVID-19 cases compared to controls. Although studies that included controls showed, on the whole, lower net prevalence of Long Covid than studies that did not, the evidence from most of these studies is that COVID-19 is associated with a substantially higher risk of being ill 12 weeks after infection than those not infected. The risk difference between cases and controls is likely dependent on the approach to control selection, whether based on self-report of absence of infection history or lab results that are not accurate enough to ascertain the state of previous infection (antigen or antibody), and timing of assessment given the predominant episodic nature of Long Covid.

The UK's Office for National Statistics (ONS) produces regular population-level estimates on the prevalence of Long Covid where the denominator is the whole population in the specific reported population group, for example, by age, sex, or occupation(142). These fall out of our inclusion criteria but are of equal importance to consider from a public health point of view as these incorporate how common the infection is in the general population at various time-periods. The ONS also produced prevalence estimates based on following up those with confirmed SARS-CoV2 infection and we used the most recent estimate within the review's search period(81). This study assessed the prevalence of Long Covid using multiple approaches including assessing individual symptoms compared to controls and asking participants if they believe they have Long Covid. The latter approach, in the absence of a standardised method of assessment, may realistically be the best way to assess the presence of Long Covid as most people will take the combination of their symptoms, duration, fluctuation, effect on functional ability and change from pre-COVID19 health to shape their responses.

The lack of consensus on the precise definition of Long Covid plays an important part in the wide differences in prevalence assessments, however we found that specifically the way the question is asked and the source of retrieved clinical information at follow-up are likely to play a crucial role. The ONS study is an example of how different methods of assessment at time of follow-up can produce substantially different Long Covid estimates(81). This was illustrated by our analysis where studies that asked about multiple symptoms/domains tended to report higher prevalence estimates than single domain studies. These include symptoms that may not necessarily impact on everyday activity.

Studies that used questionnaires/surveys to ask participants about their symptoms, health status or quality of life, tended to report higher prevalence estimates than those that recorded symptoms from healthcare records' clinical coding. This is manifested in the prevalence from Al-Aly et al(13) studies being on the lower side in our analysis as we only included those with recorded symptoms rather than recorded post-COVID-19 pathology, and such symptoms are expected to be severe enough to prompt seeking medical help and being recorded in medical notes. Studies that had dedicated pathology follow-up and discovery of COVID-19 patients, such as scans or pulmonary function tests, tended to report the highest prevalence. This is possibly because, in addition to pathology that leads to recognisable signs and symptoms, specific medical investigations as part of the research protocol can pick up latent pathology that may not be accompanied by symptoms or functional disability, at the time of assessment.

Studies such as Al-Aly et al investigating medical diagnoses in the period following COVID-19, report cardiovascular, neurological, and other system-specific clinical sequelae providing a substantial excess burden in those who survived the acute phase of COVID-19(13). However, there is no agreement yet whether these outcomes are classed as Long Covid. They are generally not recorded by symptom studies and the WHO does not yet specifically include such outcomes within its clinical

case definition of Post-COVID-19 Condition (also known as Long Covid) as it excludes those with an ‘alternative diagnosis’ that explains their symptoms/ill health (1). A specific pathology diagnosed after COVID-19 could have been triggered by the infection, but identification as such will depend on the extent of clinical investigations identifying and labelling specific pathology as opposed to differences in the disease manifestation themselves.

Other sources of heterogeneity between studies include study design as some were cross-sectional with assessment taking place at one point in time, whereas others were longitudinal where assessment of COVID-19 status was conducted prior to the development of Long Covid. This assessment itself varied in terms of using PCR or antigen testing or self-reporting of history of acute infection. Studies requiring positive PCR tests may tend towards including more symptomatic cases who sought testing.

Ideally, excess absolute risk in comparison to controls is a good measure to estimate the burden of Long Covid. Control data was primarily from participants testing antigen-negative for SARSCoV2, but some of these may have previously been infected, meaning any prolonged symptoms could be attributed to infection leading to contamination between cases and controls. Similarly, control data for untested participants may have included asymptomatic cases. For example, control groups that are household or other contacts may be more likely to include false negatives and/or asymptomatic cases.

Few studies had a low risk of bias, which suggests there is a gap in the evidence base for strong studies of Long Covid prevalence. In terms of causal inference, many studies were liable to potential collider bias, which presented as selection bias caused by restricting analyses to people who were hospitalised, self-selected for PCR or lateral flow tests based on symptoms, or simply volunteered their study participation(143). Similarly, our exploration of potential sources of heterogeneity may be prone to table 2 fallacy in the original studies, where these subgroups do not derive from the focal research question, so should be interpreted descriptively rather than causally(144).

The strengths of our review include comprehensive electronic searching for relevant studies and comprehensive assessment of risk of bias, data extraction and checking with each of these processes being done independently by two authors. We also adapted the Newcastle-Ottawa scale (Table 1) for this prevalence systematic review which can be used by other researchers for risk assessment and/or to build high quality study designs. The quality assessment criteria and process were discussed within the study team which includes two authors with lived experience of Long Covid.

Our review was limited by the substantial between study heterogeneity, such as the way symptoms were reported in the individual studies. We used the most common reported symptom estimate for studies and did not combine multiple individual symptoms into one overall estimate of prevalence of Long Covid. The symptom with the highest prevalence differed from study to study, so may not be entirely comparable. We did not include more recent studies that assessed the prevalence of Long Covid following infection with different variants of SARSCoV2 and/or in double or triple vaccinated populations. Recent ONS estimates point to a prevalence of 4-5% of reporting Long Covid at 12 to 16 weeks after first confirmed SARSCoV2 infection depending on variant, with no evidence of difference in the odds of reporting Long Covid between variants among those who are triple vaccinated when infected(145). In those double vaccinated, the prevalence of persistent symptoms was around 10% compared to 15% of unvaccinated controls(146).

We extracted estimates of “new-onset” Long Covid/symptoms where possible. Where the proportion is of a symptom like fatigue for example, we picked the one quoted as new-onset fatigue

if available, or we downgraded quality because it was not possible to ascertain that the symptom is 'new' following infection. Because Long Covid is a novel condition, prevalence of the condition is considered equivalent to cumulative incidence. When comparing with controls, we estimated cumulative incidence from reported absolute risk, when appropriate. When reporting risk ratio, we included incidence rate ratio and hazard ratios, but did not consider the odds ratio an adequate approximation because of the high potential prevalence in some populations.

We know that significant numbers of people experience persistent symptoms and pathology following SARS-CoV2 infection. Especially when people's activities of daily living are affected, Long Covid impacts on society, particularly in places with continuing waves of infection. Through reviewing how different research approaches attempted to quantify the population burden of Long Covid, our findings provide insight into how to get more accurate estimates of prevalence and severity. With quantification of prevalence, we can understand the investment needed for prevention, diagnosis and treatment as well as the policy decisions needed to resource healthcare and social care services and to mitigate the wider social and economic impact of Long Covid.

Contributors

NAA, DCG, RT, AA, VL, MW conceptualised and designed the study. MW drafted the protocol and search strategy with input from all co-authors. VL conducted the search. All authors contributed to screening the articles. MW, DCG, NZ, RT, CC extracted and quality-assessed the data. NAA, MW, DCG, NZ, CC contributed to the process of checking and verifying the extracted data. DCG planned and conducted the statistical analyses and produced the forest plots. MW, DCG, NZ, NAA interpreted the data and drafted the manuscript. All authors reviewed the final manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Declarations of interest

The authors declare no competing interests.

Data sharing

All data used in this review is available in the published included studies. Data extractions and analytic code is available from the authors on reasonable request.

Acknowledgements

We thank Hannah Davies for her input in conceptualising this review. MW was supported by an NIHR Pre-doctoral Local Authority Fellowship (Ref: 302098). RT and VL are supported by the Research, Evidence and Development Initiative (READ-It: project number 300342-104) which is funded by UK aid from the UK government. NZ is supported by NIHR Applied Research Collaboration Wessex. DCG is a co-investigator on the NIHR-funded LOCOMOTION study. NAA has lived experience of Long Covid, is a co-investigator on the NIHR-funded STIMULATE-ICP and HI-COVE studies, has contributed in an advisory capacity to WHO and the EU Commission's Expert Panel on effective ways of investing in health meetings in relation to post-COVID-19 condition, and has acted as a collaborator on some of the UK's Office for National Statistics outputs on the prevalence of Long Covid. AA has lived experience of Long Covid, is a co-founder of the Patient-Led Research Collaborative and has contributed in an advisory capacity to NIH, CDC and WHO. The views and opinions expressed in this review are those of the authors and do not necessarily reflect those of the NIHR, the Department of Health and Social Care or the UK government's official policies.

For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

References

1. World Health Organisation. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Internet; 2021 2021.
2. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. Internet; 2022. Contract No.: 1.14.
3. Centers for Disease Control and Prevention (CDC). Post-COVID Conditions: Overview for Healthcare Providers. Internet; 2021 9 July 2021.
4. Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F, et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. *Annals of Internal Medicine*. 2020;174(5):723-5.
5. Ziauddeen N, Gurdasani D, O'Hara ME, Hastie C, Roderick P, Yao G, et al. Characteristics and impact of Long Covid: Findings from an online survey. *PLOS ONE*. 2022;17(3):e0264331.
6. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *eClinicalMedicine*. 2021;38.
7. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services. *BMC Health Services Research*. 2020;20(1):1144.
8. Kingstone T, Taylor AK, Donnell CA, Atherton H, Blane DN, Chew-Graham CA. Finding the 'right' GP: a qualitative study of the experiences of people with long-COVID. *BJGP Open*. 2020;4(5):bjgpopen20X101143.
9. WHO COVID-19 Research Database [Internet]. 2022. Available from: <https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/>.
10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
11. StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021.
12. Abdelrahman MM, Abd-Elrahman NM, Bakheet TM. Persistence of symptoms after improvement of acute COVID19 infection, a longitudinal study. *Journal of medical virology*. 2021;93(10):5942-6.
13. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*. 2021;594(7862):259-64.
14. Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. Long COVID in a prospective cohort of home-isolated patients. *Nature medicine*. 2021;27(9):1607-13.
15. Aminian A, Bena J, Pantalone KM, Burguera B. Association of obesity with postacute sequelae of COVID-19. *Diabetes, Obesity & Metabolism*. 2021;23(9):2183-8.
16. Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort. *Thorax*. 2021;76:399-401.
17. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. *The Lancet Regional Health Europe*. 2021;6:100122.
18. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ (Clinical research ed)*. 2021;372:n693.
19. Baricich A, Borg MB, Cuneo D, Cadario E, Azzolina D, Balbo PE, et al. Midterm functional sequelae and implications in rehabilitation after COVID-19: a cross-sectional study. *European journal of physical and rehabilitation medicine*. 2021;57(2):199-207.
20. Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, et al. Assessment of Cognitive Function in Patients After COVID-19 Infection. *JAMA network open*. 2021;4(10):e2130645.

21. Bellan M, Soddu D, Balbo PE, Baricich A, Zeppego P, Avanzi GC, et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. *JAMA network open*. 2021;4(1):e2036142.
22. Blanco JR, Cobos-Ceballos MJ, Navarro F, Sanjoaquin I, Arnaiz de Las Revillas F, Bernal E, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. *Clinical Microbiology & Infection*. 2021;27(6):892-6.
23. Bliddal S, Banasik K, Pedersen OB, Nissen J, Cantwell L, Schwinn M, et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. *Scientific Reports*. 2021;11(1):13153.
24. Boscolo-Rizzo P, Guida F, Polesel J, Marcuzzo AV, Capriotti V, D'Alessandro A, et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). *International Forum of Allergy and Rhinology*. 2021.
25. Carrillo-Garcia P, Garmendia-Prieto B, Cristofori G, Montoya IL, Hidalgo JJ, Feijoo MQ, et al. Health status in survivors older than 70 years after hospitalization with COVID-19: observational follow-up study at 3 months. *European geriatric medicine*. 2021;12(5):1091-4.
26. Caruso D, Guido G, Zerunian M, Polidori T, Lucertini E, Pucciarelli F, et al. Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up. *Radiology*. 2021;301(2):E396-E405.
27. Caspersen IH, Magnus P, Trogstad L. Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort. *European Journal of Epidemiology*. 2022;37(5):539-48.
28. Castro VM, Rosand J, Giacino JT, McCoy TH, Perlis RH. Case-control study of neuropsychiatric symptoms in electronic health records following COVID-19 hospitalization in 2 academic health systems. *Molecular Psychiatry*. 2022.
29. Chai C, Feng X, Lu M, Li S, Chen K, Wang H, et al. One-year mortality and consequences of COVID-19 in cancer patients: A cohort study. *IUBMB life*. 2021;73(10):1244-56.
30. Cirulli ET, Schiabor Barrett KM, Riffle S, Bolze A, Neveux I, Dabe S, et al. Long-term COVID-19 symptoms in a large unselected population. *medRxiv*. 2020:2020.10.07.20208702.
31. Clavario P, De Marzo V, Lotti R, Barbara C, Porcile A, Russo C, et al. Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up. *International journal of cardiology*. 2021;340:113-8.
32. Cristillo V, Pilotto A, Cotti Piccinelli S, Zoppi N, Bonzi G, Gipponi S, et al. Age and subtle cognitive impairment are associated with long-term olfactory dysfunction after COVID-19 infection. *Journal of the American Geriatrics Society*. 2021;69(10):2778-80.
33. Diaz-Fuentes G, Roa-Gomez G, Reyes O, Singhal R, Venkatram S. Coronavirus Pneumonia: Outcomes and Characteristics of Patients in an Inner-City Area after 3 Months of Infection. *Journal of clinical medicine*. 2021;10(15).
34. Domenech-Montoliu S, Puig-Barbera J, Pac-Sa MR, Vidal-Utrillas P, Latorre-Poveda M, Rio-Gonzalez AD, et al. ABO Blood Groups and the Incidence of Complications in COVID-19 Patients: A Population-Based Prospective Cohort Study. *International journal of environmental research and public health*. 2021;18(19).
35. Erol N, Alpınar A, Erol C, Sari E, Alkan K. Intriguing New Faces Of Covid-19: persisting Clinical Symptoms And Cardiac Effects in Children. *Cardiology in the young*. 2021:1-27.
36. Evans RA, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. *The Lancet Respiratory Medicine*. 2022;10(8):761-75.
37. Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. *The Lancet Respiratory Medicine*. 2021;9(11):1275-87.
38. Fernandez-de-Las-Penas C, Gomez-Mayordomo V, de-la-Llave-Rincon AI, Palacios-Cena M, Rodriguez-Jimenez J, Florencio LL, et al. Anxiety, depression and poor sleep quality as long-

- term post-COVID sequelae in previously hospitalized patients: A multicenter study. *The Journal of infection*. 2021;83(4):496-522.
39. Fernandez-de-Las-Penas C, Guijarro C, Plaza-Canteli S, Hernandez-Barrera V, Torres-Macho J. Prevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study. *Lung*. 2021;199(3):249-53.
 40. Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, Rodriuez-Jimenez J, Palacios-Cena M, Velasco-Arribas M, et al. Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study. *Journal of Infection*. 2021;83(2):237-79.
 41. Frija-Masson J, Debray MP, Boussouar S, Khalil A, Bancal C, Motiejunaite J, et al. Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study. *Respiratory Medicine*. 2021;184:106435.
 42. Froidure A, Mahsouli A, Liistro G, De Greef J, Belkhir L, Gerard L, et al. Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae. *Respiratory medicine*. 2021;181:106383.
 43. Fu L, Fang Y, Luo D, Wang B, Xiao X, Hu Y, et al. Pre-hospital, in-hospital and post-hospital factors associated with sleep quality among COVID-19 survivors 6 months after hospital discharge: cross-sectional survey in five cities in China. *BJPsych open*. 2021;7(6):e191.
 44. Gaber TAK, Ashish A, Unsworth A. Persistent post-covid symptoms in healthcare workers. *Occupational Medicine (Oxford)*. 2021;71(3):144-6.
 45. Garcia-Abellan J, Padilla S, Fernandez-Gonzalez M, Garcia JA, Agullo V, Andreo M, et al. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. *Journal of clinical immunology*. 2021;41(7):1490-501.
 46. Garratt AM, Ghanima W, Einvik G, Stavem K. Quality of life after COVID-19 without hospitalisation: Good overall, but reduced in some dimensions. *The Journal of infection*. 2021;82(5):186-230.
 47. Gonzalez-Hermosillo JA, Martinez-Lopez JP, Carrillo-Lampon SA, Ruiz-Ojeda D, Herrera-Ramirez S, Amezcua-Guerra LM, et al. Post-Acute COVID-19 Symptoms, a Potential Link with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort. *Brain sciences*. 2021;11(6).
 48. Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. *Radiology*. 2021;299(1):E177-E86.
 49. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. *JAMA*. 2021;325(19):2015-6.
 50. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet (London, England)*. 2021;397(10270):220-32.
 51. Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. *Lancet (London, England)*. 2021;398(10302):747-58.
 52. Jacobson KB, Rao M, Bonilla H, Subramanian A, Hack I, Madrigal M, et al. Patients With Uncomplicated Coronavirus Disease 2019 (COVID-19) Have Long-Term Persistent Symptoms and Functional Impairment Similar to Patients with Severe COVID-19: A Cautionary Tale During a Global Pandemic. *Clinical Infectious Diseases*. 2021;73(3):e826-e9.
 53. Kashif A, Chaudhry M, Fayyaz T, Abdullah M, Malik A, Anwer JMA, et al. Follow-up of COVID-19 recovered patients with mild disease. *Scientific Reports*. 2021;11(1):13414.
 54. Kim Y, Kim S-W, Chang H-H, Kwon KT, Bae S, Hwang S. Significance and Associated Factors of Long-Term Sequelae in Patients after Acute COVID-19 Infection in Korea. *Infection & chemotherapy*. 2021;53(3):463-76.
 55. Lemhofer C, Sturm C, Loudovici-Krug D, Best N, Gutenbrunner C. The impact of Post-COVID-Syndrome on functioning - results from a community survey in patients after mild and

- moderate SARS-CoV-2-infections in Germany. *Journal of Occupational Medicine & Toxicology*. 2021;16(1):45.
56. Li X, Shen C, Wang L, Majumder S, Zhang D, Deen MJ, et al. Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study. *Respiratory Research*. 2021;22(1):203.
 57. Liao T, Meng D, Xiong L, Wu S, Yang L, Wang S, et al. Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan. *Infectious Diseases and Therapy*. 2021.
 58. Liao X, Wang Y, He Z, Yun Y, Hu M, Ma Z, et al. Three-Month Pulmonary Function and Radiological Outcomes in COVID-19 Survivors: A Longitudinal Patient Cohort Study. *Open forum infectious diseases*. 2021;8(9):ofaa540.
 59. Liu Y-H, Wang Y-R, Wang Q-H, Chen Y, Chen X, Li Y, et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. *Molecular neurodegeneration*. 2021;16(1):48.
 60. Liyanage-Don NA, Cornelius T, Sanchez JE, Trainor A, Moise N, Wainberg M, et al. Psychological Distress, Persistent Physical Symptoms, and Perceived Recovery After COVID-19 Illness. *Journal of General Internal Medicine*. 2021;36(8):2525-7.
 61. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA network open*. 2021;4(2):e210830.
 62. Lucidi D, Molinari G, Silvestri M, De Corso E, Guaraldi G, Mussini C, et al. Patient-reported olfactory recovery after SARS-CoV-2 infection: A 6-month follow-up study. *International Forum of Allergy & Rhinology*. 2021;11(8):1249-52.
 63. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Pang P, et al. Long COVID in Patients With Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role? *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*. 2021;27(9):894-902.
 64. Maestre-Muniz MM, Arias A, Mata-Vazquez E, Martin-Toledano M, Lopez-Larramona G, Ruiz-Chicote AM, et al. Long-Term Outcomes of Patients with Coronavirus Disease 2019 at One Year after Hospital Discharge. *Journal of clinical medicine*. 2021;10(13).
 65. Martinez AE, Banderet F, Labhardt ND, Battegay M. Long-term outcome after SARS-CoV-2 infection in healthcare workers: a single centre cohort study. *Swiss medical weekly*. 2021;151:w30094.
 66. Matteudi T, Luciani L, Fabre A, Minodier P, Boucekine M, Bosdure E, et al. Clinical characteristics of paediatric COVID-19 patients followed for up to 13 months. *Acta paediatrica*. 2021.
 67. Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. *Brain, behavior, and immunity*. 2021;94:138-47.
 68. Mechi A, Al-Khalidi A, R ALD, Al-Dujaili MN, Al-Buthabhak K, Alareedh M, et al. Long-term persistent symptoms of COVID-19 infection in patients with diabetes mellitus. *International Journal of Diabetes in Developing Countries*. 2021.
 69. Mei Q, Wang F, Bryant A, Wei L, Yuan X, Li J. Mental health problems among COVID-19 survivors in Wuhan, China. *World psychiatry : official journal of the World Psychiatric Association (WPA)*. 2021;20(1):139-40.
 70. Mei Q, Wang F, Yang Y, Hu G, Guo S, Zhang Q, et al. Health Issues and Immunological Assessment Related to Wuhan's COVID-19 Survivors: A Multicenter Follow-Up Study. *Frontiers in medicine*. 2021;8:617689.
 71. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. *PLoS ONE [Electronic Resource]*. 2021;16(7):e0254523.

72. Milanese M, Anselmo M, Buscaglia S, Garra L, Goretti R, Parodi L, et al. COVID-19 6 months after hospital discharge: pulmonary function impairment and its heterogeneity. *ERJ open research*. 2021;7(3).
73. Millet C, Narvani S, Chaudhry S, Shamoony Y, Chaudhry A, Farokhian A, et al. The Long Haul: a follow up study of patients diagnosed with COVID-19 one year ago at an urban medical center in New Jersey. *Chest*. 2021;160(4):A566-A7.
74. Mohiuddin Chowdhury ATM, Karim MR, Ali MA, Islam J, Li Y, He S. Clinical Characteristics and the Long-Term Post-recovery Manifestations of the COVID-19 Patients-A Prospective Multicenter Cross-Sectional Study. *Frontiers in Medicine*. 2021;8:663670.
75. Munblit D, Bobkova P, Spiridonova E, Shikhaleva A, Gamirova A, Blyuss O, et al. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology*. 2021;51(9):1107-20.
76. Nabahati M, Ebrahimpour S, Khaleghnejad Tabari R, Mehraeen R. Post-COVID-19 pulmonary fibrosis and its predictive factors: a prospective study. *Egyptian Journal of Radiology and Nuclear Medicine*. 2021;52(1) (no pagination)(248).
77. Nehme M, Brailard O, Chappuis F, Courvoisier DS, Guessous I, CoviCare Study T. Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting. *Annals of internal medicine*. 2021;174(9):1252-60.
78. Nguyen N, Hoang VT, Lagier JC, Raoult D, Gautret P. Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. *Clinical microbiology and infection*. 2021.
79. Nunez-Fernandez M, Ramos-Hernandez C, Garcia-Rio F, Torres-Duran M, Nodar-Germinas A, Tilve-Gomez A, et al. Alterations in Respiratory Function Test Three Months after Hospitalisation for COVID-19 Pneumonia: Value of Determining Nitric Oxide Diffusion. *Journal of Clinical Medicine*. 2021;10(10):14.
80. O'Keefe JB, Minton HC, Morrow M, Johnson C, Moore MA, O'Keefe GAD, et al. Postacute Sequelae of SARS-CoV-2 Infection and Impact on Quality of Life 1-6 Months After Illness and Association With Initial Symptom Severity. *Open forum infectious diseases*. 2021;8(8):ofab352.
81. Office for National Statistics. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. In: Statistics OfN, editor. Office for National Statistics2021.
82. Ong SWX, Fong S-W, Young BE, Chan Y-H, Lee B, Amrun SN, et al. Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. *Open forum infectious diseases*. 2021;8(6):ofab156.
83. Orru G, Bertelloni D, Diolaiuti F, Mucci F, Di Giuseppe M, Biella M, et al. Long-COVID Syndrome? A Study on the Persistence of Neurological, Psychological and Physiological Symptoms. *Healthcare (Basel, Switzerland)*. 2021;9(5).
84. Osmanov I, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, et al. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. *The european respiratory journal*. 2021.
85. Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2021;27(10):1507-13.
86. Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, et al. Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. *medRxiv : the preprint server for health sciences*. 2021.
87. Petersen M, Kristiansen MF, Hanusson KD, Danielsen MEA, Steig B, Gaini S, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. *Clinical infectious diseases*. 2020.

88. Qin W, Chen S, Zhang Y, Dong F, Zhang Z, Hu B, et al. Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up. *European Respiratory Journal*. 2021;58(1):07.
89. Qu G, Zhen Q, Wang W, Fan S, Wu Q, Zhang C, et al. Health-related quality of life of COVID-19 patients after discharge: A multicenter follow-up study. *Journal of Clinical Nursing*. 2021;30(11-12):1742-50.
90. Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents. *JAMA*. 2021.
91. Rass V, Beer R, Schiefecker AJ, Kofler M, Lindner A, Mahlknecht P, et al. Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. *European journal of neurology*. 2021;28(10):3348-59.
92. Riestra-Ayora J, Yanes-Diaz J, Esteban-Sanchez J, Vaduva C, Molina-Quiros C, Larran-Jimenez A, et al. Long-term follow-up of olfactory and gustatory dysfunction in COVID-19: 6 months case-control study of health workers. *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery*. 2021;278(12):4831-7.
93. Righi E, Mirandola M, Mazzaferri F, Razzaboni E, Zaffagnini A, Erbogasto A, et al. Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19. *Infectious diseases and therapy*. 2021;10(3):1579-90.
94. Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, et al. Post COVID-19 in children, adolescents, and adults: results of a matched cohort study including more than 150,000 individuals with COVID-19. *medRxiv*. 2021:2021.10.21.21265133.
95. Romero-Duarte A, Rivera-Izquierdo M, Guerrero-Fernandez de Alba I, Perez-Contreras M, Fernandez-Martinez NF, Ruiz-Montero R, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. *BMC medicine*. 2021;19(1):129.
96. P S, Madhavan S, Pandurangan V. Prevalence, Pattern and Functional Outcome of Post COVID-19 Syndrome in Older Adults. *Cureus*. 2021;13(8):e17189.
97. Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. *Clinical Infectious Diseases*. 2022;74(7):1191-8.
98. Shang YF, Liu T, Yu JN, Xu XR, Zahid KR, Wei YC, et al. Half-year follow-up of patients recovering from severe COVID-19: Analysis of symptoms and their risk factors. *Journal of Internal Medicine*. 2021;290(2):444-50.
99. Sibila O, Albacar N, Perea L, Faner R, Torralba Y, Hernandez-Gonzalez F, et al. Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge. *Archivos de bronconeumologia*. 2021;57:59-61.
100. Sigfrid L, Drake TM, Pauley E, Jesudason EC, Olliaro P, Lim WS, et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. *The Lancet Regional Health Europe*. 2021;8:100186.
101. Simani L, Ramezani M, Darazam IA, Sagharichi M, Aalipour MA, Ghorbani F, et al. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. *Journal of neurovirology*. 2021.
102. Skala M, Svoboda M, Kopecky M, Kocova E, Hyrsil M, Homolac M, et al. Heterogeneity of post-COVID impairment: interim analysis of a prospective study from Czechia. *Virology journal*. 2021;18(1):73.
103. Skjorten I, Ankerstjerne OAW, Trebinjac D, Bronstad E, Rasch-Halvorsen O, Einvik G, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. *European Respiratory Journal*. 2021;58(2):08.

104. Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. *The European respiratory journal*. 2021;57(4).
105. Soraas A, Bo R, Kalleberg KT, Stoer NC, Ellingjord-Dale M, Landro NI. Self-reported Memory Problems 8 Months After COVID-19 Infection. *JAMA Network Open*. 2021;4(7):e2118717.
106. Soraas A, Kalleberg KT, Dahl JA, Soraas CL, Myklebust TA, Axelsen E, et al. Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study. *PLoS one*. 2021;16(8):e0256142.
107. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. *Thorax*. 2020.
108. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Prevalence and Determinants of Fatigue after COVID-19 in Non-Hospitalized Subjects: A Population-Based Study. *International journal of environmental research and public health*. 2021;18(4).
109. Stephenson T, Shafran R, De Stavola B, Rojas N, Aiano F, Amin-Chowdhury Z, et al. Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study). *BMJ open*. 2021;11(8):e052838.
110. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. *Nature medicine*. 2021;27(4):626-31.
111. Sykes D, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 Symptom Burden: what is Long-COVID and How Should We Manage It? *Lung*. 2021;199:113-119.
112. Taboada M, Carinena A, Moreno E, Rodriguez N, Dominguez MJ, Casal A, et al. Post-COVID-19 functional status six-months after hospitalization. *The Journal of infection*. 2021;82(4):e31-e3.
113. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLoS medicine*. 2021;18(9):e1003773.
114. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *The lancet Psychiatry*. 2021;8(5):416-27.
115. Tarsitani L, Vassalini P, Koukopoulos A, Borrazzo C, Alessi F, Di Nicolantonio C, et al. Post-traumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge. *Journal of general internal medicine*. 2021;36(6):1702-7.
116. Tawfik HM, Shaaban HM, Tawfik AM. Post-covid-19 syndrome in egyptian healthcare staff: Highlighting the carers sufferings. *Electronic Journal of General Medicine*. 2021;18(3) (em291).
117. Taylor R, Trivedi B, Patel N, Singh R, Ricketts WM, Elliott K, et al. Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia. *Clinical medicine (London, England)*. 2021.
118. Tempany M, Leonard A, Prior AR, Boran G, Reilly P, Murray C, et al. The potential impact of post-COVID symptoms in the healthcare sector. *Occupational medicine (Oxford, England)*. 2021;71(6-7):284-9.
119. Writing Committee for the CSG, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. *JAMA*. 2021;325(15):1525-34.
120. Tholin B, Ghanima W, Einvik G, Aarli B, Bronstad E, Skjonsberg OH, et al. Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis. *British Journal of Haematology*. 2021;194(3):542-6.
121. Tleyjeh IM, Saddik B, AlSwaidan N, AlAnazi A, Ramakrishnan RK, Alhazmi D, et al. Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up. *PLOS ONE*. 2021;16(12):e0260568.

122. Todt BC, Szlejf C, Duim E, Linhares AOM, Kogiso D, Varela G, et al. Clinical outcomes and quality of life of COVID-19 survivors: A follow-up of 3 months post hospital discharge. *Respiratory Medicine*. 2021;184:106453.
123. Tohamy D, Sharaf M, Abdelazeem K, Saleh MGA, Rateb MF, Soliman W, et al. Ocular Manifestations of Post-Acute COVID-19 Syndrome, Upper Egypt Early Report. *Journal of multidisciplinary healthcare*. 2021;14:1935-44.
124. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PLoS one*. 2020;15(11):e0240784.
125. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, et al. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. *Viruses*. 2021;13(2).
126. Ursini F, Ciaffi J, Mancarella L, Lisi L, Brusi V, Cavallari C, et al. Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. *RMD Open*. 2021;7(3):08.
127. Venturelli S, Benatti SV, Casati M, Binda F, Zuglian G, Imeri G, et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. *Epidemiology and Infection*. 2021;149:e32.
128. Walle-Hansen MM, Ranhoff AH, Mellingsaeter M, Wang-Hansen MS, Myrstad M. Health-related quality of life, functional decline, and long-term mortality in older patients following hospitalisation due to COVID-19. *BMC geriatrics*. 2021;21(1):199.
129. Weng J, Li Y, Li J, Shen L, Zhu L, Liang Y, et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. *The Lancet Gastroenterology & Hepatology*. 2021;6(5):344-6.
130. Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. *Nature Communications*. 2022;13(1):1957.
131. Xiong L, Li Q, Cao X, Xiong H, Huang M, Yang F, et al. Dynamic changes of functional fitness, antibodies to SARS-CoV-2 and immunological indicators within 1 year after discharge in Chinese health care workers with severe COVID-19: a cohort study. *BMC Medicine*. 2021;19(1):163.
132. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clinical Microbiology and Infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2021;27(1):89-95.
133. Yan B, Song L, Guo J, Wang Y, Peng L, Li D. Association Between Clinical Characteristics and Short-Term Outcomes in Adult Male COVID-19 Patients With Mild Clinical Symptoms: A Single-Center Observational Study. *Frontiers in Medicine*. 2020;7:571396.
134. Yan X, Huang H, Wang C, Jin Z, Zhang Z, He J, et al. Follow-up study of pulmonary function among COVID-19 survivors 1 year after recovery. *The Journal of Infection*. 2021;83(3):381-412.
135. Yin X, Xi X, Min X, Feng Z, Li B, Cai W, et al. Long-term chest CT follow-up in COVID-19 Survivors: 102-361 days after onset. *Annals of Translational Medicine*. 2021;9(15):1231.
136. Zayet S, Zahra H, Royer P-Y, Tipirdamaz C, Mercier J, Gendrin V, et al. Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comte Hospital, France. *Microorganisms*. 2021;9(8).
137. Zhan Y, Zhu Y, Wang S, Jia S, Gao Y, Lu Y, et al. SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection. *Signal Transduction and Targeted Therapy*. 2021;6(1) (368).
138. Zhang D, Zhang C, Li X, Zhao J, An C, Peng C, et al. Thin-section computed tomography findings and longitudinal variations of the residual pulmonary sequelae after discharge in patients with COVID-19: a short-term follow-up study. *European Radiology*. 2021;31(9):7172-83.

139. Zhang J, Xu J, Zhou S, Wang C, Wang X, Zhang W, et al. The characteristics of 527 discharged COVID-19 patients undergoing long-term follow-up in China. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2021;104:685-92.
140. Zhang X, Wang F, Shen Y, Zhang X, Cen Y, Wang B, et al. Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China. *JAMA network open*. 2021;4(9):e2127403.
141. Zhou M, Xu J, Liao T, Yin Z, Yang F, Wang K, et al. Comparison of Residual Pulmonary Abnormalities 3 Months After Discharge in Patients Who Recovered From COVID-19 of Different Severity. *Frontiers in medicine*. 2021;8:682087.
142. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 September 2022. In: *Statistics OfN*, editor. 2022.
143. Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. *Nature Communications*. 2020;11(1):5749.
144. Westreich D, Greenland S. The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients. *American Journal of Epidemiology*. 2013;177(4):292-8.
145. Office for National Statistics. Self-reported long COVID after infection with the Omicron variant in the UK: 18 July 2022. In: *Statistics OfN*, editor. 2022.
146. Ayoubkhani D, Bosworth ML, King S, Pouwels KB, Glickman M, Nafilyan V, et al. Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study. *Open Forum Infectious Diseases*. 2022.

Figure legends

Figure 1: Study selection

Figure 2: Forest plot of prevalence of Long Covid in the included studies by study design

Figure 3: Forest plot of prevalence of Long Covid in the included studies by method of outcome assessment

Figure 4: Forest plot of risk of Long Covid in included studies with community-based samples and controls assessed as having low risk of bias

Supplementary material

Supplementary appendix

Table 1: Adapted Newcastle-Ottawa Scale Risk of Bias Tool

Selection/denominator 1: Definition/diagnostic criteria	●	Confirmed by laboratory (any - Ag/Ab/PCR)
	○	clinical diagnosis – not lab confirmed
		Self-diagnosed – not lab or clinically confirmed
Selection/denominator 2: Representativeness of all COVID-19 cases in the population (adult or children)	●	Representative of community-based COVID19 cases
		hospitalised only
		<70% response rate or response rate not stated
		Intensive care patients included but proportion not stated and/or ICU patient outcome data not separated/stratified
		Healthcare workers only or other demographic-specific e.g. age, gender
		Pre-existing condition patient group e.g. transplant patients Specific groups e.g. support groups
Selection/denominator 3: Outcome of interest (LC symptoms) was not present prior to infection	●	Health status assessment pre-coronavirus
		No health status assessment
	●	Comparison to test-negative controls
Comparability: Source of participants without LC symptoms	●	Drawn from same source as those with LC symptoms
		drawn from a different source
		no description
Outcome/numerator 1: Systematic assessment	●	All participants assessed
		Targeted/unstructured
		Different methods of data collection used for different participants
Outcome/numerator 2: Quality of assessment	●	Clinician diagnosis of LC symptoms/pathology using a structured approach
	●	Systematic symptoms/pathology assessment
	●	Standardised rating scales
	●	High-quality qualitative methods
		Unstructured reporting of diagnosis, symptoms or severity
Outcome/numerator 3: Comprehensiveness of LC symptoms/pathology assessed	●	Good range of LC symptoms assessed with severity captured
		Few symptoms assessed
		single pathology assessed
Outcome/numerator 4: Follow-up period	●	Same time-point for all, follow-up time adequate
		Follow-up time-point based on hospital admission or length of hospitalisation, with no indication of symptom-onset or test date
		Unclear length of illness
		Not all patients discharged, so actual length of illness unknown
Outcome/numerator 5: Loss to follow-up	●	complete follow-up – all subjects accounted for
	●	subjects lost to follow-up unlikely to introduce bias – small number lost [> 70% followed-up] or description provided of those lost
		no statement
		no follow-up (cross-sectional)
Outcome/numerator 6: Effect of interventions	●	Differential effect of intervention considered e.g. treatment
		No consideration of interventions

Table 2 – Study characteristics and findings of first follow-up

Papers coded variously with the following symbols are different publications from the same study data: Ω, ▪, ◊, ¥, †, ∞, π

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
1.	Abdelrahman, M et al(1)	Egypt	Prospective cohort	172	-	Hospitalised patients and non-hospitalised	41.8/17.6	65.7	'Tested positive'	12.8% hospitalised (including 4% ICU)	240-300 (range) following 'improvement of acute COVID-19'	61.0%
2.	Al-Aly, Z et al(2)	USA	Cohort with controls	60255	4526737 without COVID-19 and not hospitalised	Non-hospitalised	61 (4872)	12.1	'Positive test'	-	126 ^b	2.9%
2a.	Al-Aly, Z et al (2)	USA	Cohort with controls	11800	11868 hospitalised with seasonal influenza	Hospitalised patients	70 (61-76)	5.8	PCR confirmed	26.3% ICU	150 ^b	9.2%
3.	Aminian, A et al (3)	USA	Retrospective	2839	-	Hospitalised patients	52.7/20.1	52.3	PCR confirmed	ICU excluded	243 ^b	44.2%
4.	Arnold, D et al(4)	UK	Prospective cohort	110	-	Hospitalised patients	60 (46-73)	44.0	PCR confirmed or clinico-radiological	Mixed	90 ^b	73.6%
5.	Augustin, M et al(5)	Germany	Longitudinal prospective cohort	442	-	Non-hospitalised patients	43 (31-54)	52.3	PCR confirmed	97.5% mild	131 ^b	27.8%
6.	Ayoubkhani, D et al(6)	UK	Observational retrospective matched cohort (with controls)	47780	47780 matched for age, sex	Hospitalised patients	64.5/19.2	45.1	Laboratory confirmed or clinical diagnosis	9.9% ICU	140 ^e	21.5
7.	Baricich, A et al(7)	Italy	Cross-sectional	204	-	Hospitalised patients	57.9/12.8	40.0	'Confirmed diagnosis'	13% ICU	124.7 ^e	32.4%
8.	Becker, J et al(8)	USA	Cross-sectional	740	-	Hospitalised patients,	49 (38-59)	63.0	Tested positive or	-	228 ^a	24.1%

¹ Different denominators specific to each outcome have been used in cases where data are incomplete or where individual symptoms have different denominators.

² a – mean no. of days post-symptom onset or positive test; b - median no. of days post-symptom onset or positive test; c – mean no. of days post-hospital admission; d - median no. of days post-hospital admission; e – mean no. of days post-hospital discharge; f – median no. of days post-hospital discharge; g – mean no. of days post-negative test following infection; h - median no. of days post-negative test following infection

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
						outpatients and ER attendees			antibody positive			
9.	Bellan, M et al(9)	Italy	Prospective cohort	238	-	Hospitalised patients	61 (50-71)	40.3	PCR confirmed bronchial swab, serological testing, or suggestive CT	27.7% did not require oxygen 11.8% ICU	91-121 ^e	53.8%
10.	Blanco, J et al(10)	Spain	Prospective	100	-	Hospitalised patients	54.9/10.3	36.0	PCR confirmed	47% severe	104 ^b	52.0%
11.	Bliddal, S et al(11)	Denmark	Cohort	129	-	Non-hospitalised patients	44.8 (13.6)	70.0	PCR confirmed	Non-hospitalised	90 ^a	40.3%
12.	Blomberg, B et al(12)	Norway	Prospective cohort with controls	312	60 seronegative household contacts	Hospitalised patients and non-hospitalised	46 (30-58)	51.0	'Tested positive'	2% asymptomatic, 78% symptomatic in community, 21% hospitalised	152-213 (range) after illness	60.6%
13.	Boscolo-Rizzo, P et al(13)	Italy	Prospective	304	-	Community	47 (n/a)	60.9	PCR confirmed	Mild-to-moderate (home-isolated)	365 ^a	53.0%
14.	Carrillo-Garcia, P et al(14)	Spain	Longitudinal observational	165	-	Hospitalised older adult patients	88.5/6.7	69.1	PCR confirmed and suspected cases (clinical, imaging and laboratory results)	-	3m post-hospital discharge	66.2%
15.	Caruso, D et al(15)	Italy	Prospective	118	-	Hospitalised patients with interstitial pneumonia	65/12	53.0	PCR confirmed	Moderate to severe	6m post-hospital admission	77.1%
16.	Caspersen, I et al(16)	Norway	Matched cohort	774	72953	Community (MoBa: population-	25+	58.0	PCR confirmed	-	334-365 (range) after infection	16.5%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
						based pregnancy cohort study)						
17.	Castro, V et al(17)	USA	Retrospective cohort	5571	30193 hospitalised COVID-19 negative patients	Hospitalised patients	63 (50-76)	47.0	PCR confirmed	13% ICU	91-150 days post-hospital admission	10.9%
18.	Chai, C et al(18)	China	Multi-centre ambidirectional cohort	546	-***	Hospitalised cancer and non-cancer patients	65 (59-70)	51.0	PCR confirmed	24% severe	370 ^d	28.6%
19.	Cirulli, E et al(19)	USA	Prospective longitudinal	357	-	Community	-	-	PCR confirmed	-	90 ^a	14.8%
20.	Clavario, P et al(20)	Italy	Prospective cohort	200	-	Hospitalised patients	58.8 (51.6-66.0)	43.0	PCR confirmed	89% required at least oxygen support	107 ^f	80.0%
21.	Cristillo, V et al(21)	Italy	Cohort*	101	-	Hospitalised patients	63.6/12.9	27.7	'Hospitalised for COVID-19'	hospitalized for mild to moderate COVID	6m post-hospital discharge	49.5%
22.	Diaz-Fuentes, G et al(22)	USA	Retrospective cohort	111	-	Hospitalised patients and non-hospitalised	60/13.9	53.1	Positive nasal swab	Mixed	12 weeks post-infection	79.3%
23.	Domenech-Montoliu, S et al(23)	Spain	Prospective cohort	483	-	Community	37.2/17.1	62.1	Laboratory confirmed	11.2% asymptomatic	7m post-infection	53.4%
24.	Erol, N et al(24)	Turkey	Cohort	121	95 randomly selected from non-COVID patients attending the ward	Hospitalised and non-hospitalised children	9.2 (10.9-17.9)	46.2	'Tested positive'	22.3% hospitalised	5.6m post-infection	37.2%
25.	Evans R, et al (PHOSP-COVID study) (25) (¥)	UK	Prospective longitudinal cohort	804	-	Hospitalised patients	58.0/12.6	39.0	PCR confirmed or	Mixed	365 ^f	48.8%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
									clinician diagnosed			
26.	Evans, R et al (PHOSP-COVID study)(26) (¥)	UK	Prospective longitudinal cohort	1077	-	Hospitalised patients	57.9/13	35.7	Confirmed or clinician-diagnosed	Mixed	176 ^f	92.6%
27.	Fernandez-de-Las-Penas, C et al(27) (∞)	Spain	Multi-centre observational	1142	-	Hospitalised patients	61/17	47.5	PCR confirmed	7% ICU	210 ^e	81.4%
28.	Fernandez-de-Las-Penas, C et al(28) (∞)	Spain	Multicentre observational	1142	-	Hospitalised patients	61/17	47.4	PCR confirmed	7% ICU	210 ^e	49.6%
29.	Fernandez-de-Las-Penas, C et al(29) (∞)	Spain	Multi-centre cohort	1950	-	Hospitalised patients	61/16	46.9	PCR confirmed	6.6% ICU	340 ^e	81.2%
30.	Frija-Masson, J et al(30)	France	Retrospective	137	-	Not stated	59 (50-68)	49.0	PCR confirmed	90.5% required respiratory support	3m post-symptom onset	75.2%
31.	Froidure, A et al(31)	Belgium	Single-centre cohort	107	-	Hospitalised patients	60 (53-68)	41.0	PCR confirmed	Severe and critical	103 ^b	68.2%
32.	Fu, L et al(32)	China	Cross-sectional	199	-	Hospitalised patients	18+	53.3	Not stated	2.5% ICU	6m post-hospital discharge	10.1%
33.	Gaber, T et al(33)	UK	Cross-sectional	138	-	98% non-hospitalised health care workers	-	92.0	83% PCR confirmed 17% no laboratory confirmation	2% hospitalised	4m post-infection	44.2%
34.	Garcia-Abellan, J et al(34)	Spain	Prospective longitudinal	116	-	Hospitalised patients	64 (54-76)	39.7	PCR confirmed	14% ICU	180 ^a	24.1%
35.	Garratt, A et al(35) (•)	Norway	Cross-sectional survey of a geographical cohort	447	Norwegian general population norms	Community	49.5/15.3	56.0	PCR confirmed	Non-hospitalised	117.5 ^b	35.3%
36.	Gonzalez-Hermosillo, J et al(36)	Mexico	Prospective longitudinal	130	-	Hospitalised patients	51/14	34.6	PCR confirmed	Moderate to severe	3m post-hospital discharge	91.5%
37.	Han, X et al(37)	China	Prospective longitudinal	114	-	Hospitalised patients	54/12	30.0	PCR confirmed	Severe	175 ^a	62.3%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
38.	Havervall, S et al(38)	Sweden	Cohort with controls	323	1072 seronegative	Health care workers	43 (33-52)	83.0	Seropositive	mild/moderate (severe excluded)	122 ^a	21.4%
39.	Huang, C et al(39) (Ω)	China	Ambidirectional cohort	1655	-	Hospitalised patients	57 (47-65)	48.0	Laboratory confirmed	68% required oxygen therapy 4% ICU	186 ^b	76.4%
40.	Huang, L et al(40) (Ω)	China	Ambidirectional cohort with controls	1227	3383 community dwelling without SARS-CoV-2 infection, 1164 matched pairs	Hospitalised patients	59 (49-67)	47.0	Laboratory confirmed	4% ICU	185 ^b	68.0%
41.	Jacobson, K et al(41)	USA	Cohort*	118	-	Hospitalised patients and non-hospitalised	43.3/14.4	46.6	PCR confirmed	18.6% hospitalised 9.3% ICU	119.3 ^b	66.9%
42.	Kashif, A et al(42)	Pakistan	Cohort*	242	-	Hospitalised patients and non-hospitalised	18-65	30.6	PCR confirmed	Mild	3m post-hospital discharge or visit	41.7%
43.	Kim, Y et al(43)	S Korea	Cohort*	900	-	Hospitalised patients and non-hospitalised	31 (24-47)	69.7	PCR confirmed	12% moderate or severe	195 ^b	65.7%
44.	Lemhofer, C et al(44)	Germany	Cross-sectional	365	-	Community	49.8/16.9	59.2	'Positively tested'	Mild and moderate	93.7% - more than 3months post-infection	61.9%
45.	Li, X et al(45)	China	Cohort	289	-	Hospitalised patients	43.6/17.4	48.8	PCR confirmed	19.4% severe/critical	90-150 (range) post-symptom onset	59.9%
46.	Liao, T et al(46)	China	Cohort*	303	-	Hospitalised healthcare workers	39 (33-48)	80.5	'Infected with COVID-19'	62.7% critical/severe	395 ^f	37.3%
47.	Liao, X et al(47)	China	Longitudinal cohort	142	-	Hospitalised patients	47.5 (36-57)	48.8	PCR confirmed	21.1% severe	90 ^f	85.9%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
48.	Liu, Y-H et al(48)	China	Cross-sectional	1301	466 uninfected spouses who lived together	Hospitalised patients, elderly	68 (66-74)	53.3	'Diagnosis of COVID-19'	1.8% ICU	6m post-hospital discharge	28.7%
49.	Liyanage-Don, A et al(49)	USA	Cohort*	153	-	Hospitalised patients	54.5/16.7	39.9	'Hospitalised for COVID-19'	5.9% ICU	111 ^b	64.7%
50.	Logue, J et al(50)	USA	Longitudinal prospective cohort (cross sectional for controls*)	177	21, 'healthy controls recruited via email and flyer advertisements'	Hospitalised and outpatients	48 / 15.2	57.1	laboratory-confirmed	6.2% asymptomatic, 84.7% mild illness, 9.0% moderate or severe disease	169 ^b	30.0%
51.	Lucidi, T et al(51)	Italy	Observational retrospective	110	-	Not stated	41.4/12.3	63.6	'COVID-19 positive patients'	-	6.1 +/- 1.1 months post-infection	36.4%
52.	Lui, D et al(52)	China (HK)	Prospective	204	-	Hospitalised patients	55 (44-63)	53.4	PCR confirmed	3.9% severe	89 ^d	20.1%
53.	Maestre-Muniz, M et al(53)	Spain	Cross-sectional	543	-	Hospitalised patients and ER attendees	65.1/17.5	49.3	Laboratory confirmed	Mixed	12m post-hospital discharge	56.9%
54.	Martinez, A et al(54)	Switzerland	Retrospective cohort	260	-	Healthcare workers	Mean range 30-39	75.4	'Positive test'	1.2% hospitalised	168 ^b	26.5%
55.	Matteudi, T et al(55)	France	Prospective cohort	137	-	Hospitalised patients and outpatients, paediatric	9.3 (n/a)	-	PCR confirmed	27% asymptomatic	180 ^a	16.8%
56.	Mazza, M et al(56)	Italy	Prospective cohort	226	-	Hospitalised patients and ER attendees	58.5/12.8	34.1	PCR confirmed	78% hospitalised	90.1 ^e	35.8%
57.	Mechi, A et al(57)	Iraq	Single-centre cross-sectional	112	-	Hospitalised patients and non-hospitalised	50.6/13.4	34.0	Laboratory confirmed	46.4% hospitalised	9m after acute infection	82.1%
58.	Mei, Q et al(58) (†)	China	Cohort*	4328	1500, random sample of general population	Hospitalised patients	59 (47-68)	54.1	Met relevant clinical criteria	Not defined	144 ^f	14.2%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
59.	Mei, Q et al(59) (†)	China	Prospective cohort	3677	-	Hospitalised patients	59 (47-68)	55.5	PCR confirmed	33.7% severe, 2.6% critical	144 ^f	26.5%
60.	Menges, D et al(60)	Switzerland	Population-based prospective cohort	431	-	Community	47 (33-58)	49.7	PCR confirmed	10.7% asymptomatic, 38.1% severe/very severe	220 ^b	24.6%
61.	Milanese, M et al(61)	Italy	Prospective cohort	135	-	Hospitalised patients	59/11	33.0	Not stated	Moderate and severe	182 ^e	47.4%
62.	Millet, C et al(62)	USA	Prospective cohort	173	-	Hospitalised patients and outpatients	51.5/n/a	50.6	PCR confirmed	-	12m post-diagnosis	48.0%
63.	Mohiuddin Chowdhury, A et al(63)	Bangladesh	Prospective multi-centre cross-sectional	313	-	Hospitalised patients and outpatients	37.7/13.7	19.8	PCR confirmed	Not critically ill (ICU/HDU)	140 ^g	21.4%
64.	Munblit, D et al(64)	Russia	Longitudinal cohort	2649	-	Hospitalised patients	56 (46-66)	51.1	PCR confirmed and clinically diagnosed	2.6% severe	218 ^f	57.9%
65.	Nabahati, M et al(65)	Iran	Prospective cross-sectional	173	-	Hospitalised patients	53.6/13.7	67.1	PCR confirmed	54% severe	90 ^e	52.0%
66.	Nehme, M, et al(66)	Switzerland	Prospective cohort	410	-	Outpatients	42.7/12.9	67.1	PCR confirmed	Mild and moderate	7-9m post-diagnosis	39.0%
67.	Nguyen, N et al(67)	France	Cohort*	125	-	Hospitalised	36 (27-48))	55.0	PCR confirmed	Non-severe	210 ^a	24.0%
68.	Nunez-Fernandez, M et al(68)	Spain	Prospective cohort	200	-	Hospitalised patients	62 (n/a)	40.5	PCR confirmed	15.5% ICU	84 ^e	29.0%
69.	O'Keefe, J et al(69)	USA	Cross-sectional	198	-	Outpatients	45/14	74.2	PCR confirmed	29.7% moderate, 1.1% severe	119 ^b	39.9%
70.	Office for National Statistics(70)	UK	Prospective cohort w	21374	-	Community	2+	52.3	PCR confirmed	-	12 weeks post-infection	11.7%
71.	Ong, S et al(71)	Singapore	Prospective longitudinal multi-centre cohort	175	-	Hospitalised patients	44 (33-56)	24.6	PCR confirmed	30.1% severe	90 ^e	7.4%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
72.	Orru, G et al(72)	Italy	retrospective	152	-	Community via social media	-	-	Self-report	-	At least 3m post-infection	74.3%
73.	Osmanov, I et al(73)	Russia	Prospective cohort	518	-	Hospitalised children	10.4 (3.0-15.2)	52.1	PCR confirmed	2.7% severe (NIV/IV or PICU)	256 ^f	24.3%
74.	Peghin M, et al(74)	Italy	Bidirectional prospective cohort	599	-	Hospitalised patients and outpatients	53/15.8	53.4	NAAT for confirmed cases; laboratory, imaging or serology for suspected cases	Mixed	191 ^b	40.2%
75.	Peluso, M et al(75)	USA	Cohort	143	-	Hospitalised patients and non-hospitalised	48 (37-57)	44.0	RNA-confirmed	Mixed	4m post-test or first symptoms	62.2%
76.	Petersen, M et al(76)	Faroe Islands	Longitudinal	180	-	96% non-hospitalised patients	39.9/19.4	54.4	PCR confirmed	4.4% asymptomatic	125 ^a	52.8%
77.	Qin, W et al(77)	China	Prospective cohort	647	-	Hospitalised patients	58/15	56.0	PCR confirmed	38% severe	3m post-hospital discharge	13.4%
78.	Qu, G et al(78)	China	Multicentre follow-up	540	-	Hospitalised patients	47.5 (37-57)	50.0	PCR confirmed	9.4% severe	3m post-hospital discharge	32.6%
79.	Radtke, T et al(79)	Switzerland	Longitudinal cohort	109	1246 seronegative	Community, children and adolescents	6-16	53.0	Antibody positive	No hospitalisation	84 ^a	3.7%
80.	Rass, V et al(80)	Austria	Prospective observational cohort	135	-	Hospitalised and outpatients	56 (48-68)	39.0	PCR confirmed	23% severe (ICU), 53% moderate (hospitalised)	90 ^a	60.7%
81.	Riestra-Ayora, J et al(81)	Spain	Prospective case-control	195	125 healthcare workers with negative PCR	Hospitalised and non-hospitalised healthcare workers	41.6/n/a	80.0	PCR confirmed	4.4% hospitalised	6m post-positive test	26.7%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
82.	Righi, E et al(82)	Italy	Prospective cohort	421	-	Hospitalised patients and outpatients	56 (45-66)	45.1	PCR confirmed	52% hospitalised, 20% ICU	84 ^a	19.7%
83.	Roessler, M et al(83) <i>Split cohort (Adults)</i>	Germany	Matched cohort	145184	-	Community	-	60.2	'Laboratory confirmed'	5.8% hospitalised, 2.1% intensive care or ventilation	>90 ^a	9.2%
83a.	Roessler, M et al(83) <i>Split cohort (Children)</i>	Germany	Matched cohort	11950	-	Community, children	-	48.1	Laboratory confirmed	1% hospitalised, 0.4% ICU	>90 ^a	6.1%
84.	Romero-Duarte, A et al(84)	Spain	Retrospective longitudinal observational follow-up	797	-	Hospitalised patients	63/14.4	46.3	PCR confirmed	10.8% ICU	6m post-hospital discharge	63.9%
85.	Sathyamurthy, P et al(85)	India	Single-centre prospective cohort	279	-	Hospitalised older adult patients	71.0/5.6	36.2	PCR confirmed	41.6% severe to critical	90 ^e	23.7%
86.	Seeßle, J et al(86)	Germany	Prospective cohort	146	-	Hospitalised and outpatients	57 (50-63)	57.0	PCR confirmed	15.6% mild, 55.2% moderate, 25.0% severe, 4.2% critical	140-154 (range) following symptom onset	73.3%
87.	Shang, Y et al(87)	China	Cohort	796	-	Hospitalised patients	62 (51-69)	49.2	PCR confirmed	90.8% severe, 9.2% critical	6m post-hospital discharge	55.4%
88.	Sibila, O et al(88)	Spain	Prospective cohort	172	-	Hospitalised patients	56.1/19.8	43.0	Not stated	moderate and severe 43% ICU	101.5 ^e	57.0%
89.	Sigfrid, L et al(89)	UK	Prospective cohort	327	-	Hospitalised patients	59.7 (51.7-67.7)	41.3	PCR confirmed or 'clinically diagnosed highly suspected'	20.8% no O2, 36.1% supplemental O2, 15.0% non-invasive O2, 28.1%	222 ^b	93.3%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
										mechanical ventilation		
90.	Simani, L et al(90)	Iran	Cohort*	120	-	Hospitalised patients	54.6/16.9	33.3	Spiral chest CT scan or PCR confirmed	7.5% ICU	183 ^e	10.0%
91.	Skala, M et al(91)	Czech Republic	Prospective cohort	102	-	Hospitalised patients and outpatients	46.7/ n/a	53.9	PCR confirmed	14.7% hospitalised	3m after testing positive	54.9%
92.	Skjorten, I et al(92)	Norway	Multi-centre prospective cohort	126	-	Hospitalised patients	56.2/12.7	38.5	'Discharge diagnosis of COVID-19'	20% ICU	104 ^f	46.8%
93.	Sonnweber, T et al(93)	Austria	Prospective observational	145	-	Hospitalised and outpatients	57/14	43.0	PCR confirmed	22% ICU	103 ^a	54.9%
94.	Soraas, A et al(94) (π)	Norway	Cohort	651	5712 SARS-CoV-2–negative + 3342 randomly selected untested	Community	48.6/13.6	57	PCR confirmed	Non-hospitalised, mild	258 ^a	51.9%
95.	Soraas, A et al(95) (π)	Norway	Prospective cohort	672	6006 SARS-COV2-negative patients	Community	48.5/13.5	56.8	PCR confirmed	Non-hospitalised	126 ^a	56.2%
96.	Stavem, K et al(96) (•)	Norway	Cross-sectional	451	-	Community survey	49.7/15.2	56.0	PCR confirmed	-	117 ^b	41.0%
97.	Stavem, K et al(97) (•)	Norway	Cross-sectional mixed-mode	458	-	Community	49.5/15.3	56.0	PCR confirmed	-	117.5 ^b	46.0%
98.	Stephenson, T et al(98)	UK	Matched cohort	3065	3739 who tested negative	Community, adolescents	11-17	63.5	PCR confirmed	35.4% symptomatic	104 ^b	66.5%
99.	Sudre, C et al(99)	UK, USA and Sweden	Prospective observational cohort	4182	4,182, matched PCR negative***	Community	46.0/15.8	57.0	PCR confirmed	13.9% visited hospital	84 ^a	2.6%
100.	Sykes, D et al(100)	UK	Cohort*	127	-	Hospitalised patients	59.6/14	34.3	PCR confirmed	87% required oxygen and/or	113 ^f	59.1%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
										respiratory support, 20% ICU		
101.	Taboada, M et al(101)	Spain	Cross-sectional observational	183	-	Hospitalised patients	6.9/14.1	40.5	PCR confirmed	18.2% ICU	6 months post-hospitalisation	47.5%
102.	Taquet, M et al(102) (Ø)	Primarily USA	Retrospective cohort with matching	236,379	105,579 diagnosed with flu, 236,038 with any other RTI including flu	healthcare organisations including hospitals, primary care, and specialist providers	46/19.7	55.6	"confirmed diagnosis"	Mixed	180 ^a	12.8%
103.	Taquet, M et al(103) (Ø)	USA	Retrospective cohort	273618	106,578 matched cohort with influenza and without a diagnosis of COVID-19 or positive test	Hospitalised patients and non-hospitalised	46.3/19.8	55.6	'Confirmed diagnosis', ICD-10 code	Mixed	90 ^a	36.5%
104.	Tarsitani, L et al(104)	Italy	Cohort follow-up	115	-	Hospitalised patients	57 (48-66)	46.0	'Confirmed COVID-19'	23% ICU	3m post-hospital discharge	29.6%
105.	Tawfik, H et al(105)	Egypt	Retrospective cohort	120	-	Hospitalised and non-hospitalised healthcare workers	33.7/7.29	58.0	PCR confirmed	28.3% moderate, 10.0% severe	At least 3m post-positive test	33.3%
106.	Taylor, R et al(106)	UK	Cohort*	545	-	Hospitalised patients	58.6/15.3	38.2	'Presumed and confirmed'	-	16weeks post-hospital discharge	47.9%
107.	Tempany, M et al(107)	Republic of Ireland	Cross-sectional*	217	-	Healthcare workers	20-69	80.0	PCR confirmed or antibody positive	-	At least 12 weeks post- +ve test	53.5%
108.	The Writing Committee for the COMEBAC Study Group(108)	France	Prospective uncontrolled cohort	478	-	Hospitalised patients	60.9/16.1	42.1	PCR confirmed or by CT scan	29.7% ICU, remainder hospitalised	113 ^f	51.0%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
109.	Tholin, B et al(109) (•)	Norway	Multicentre prospective cohort	683	-	Hospitalised patients and non-hospitalised	52.9/15.5	51.0	PCR confirmed, or discharge diagnosis of 'confirmed or unconfirmed COVID-19'	Mixed	3m after discharge (hospitalised), 4m post-symptom onset (non-hospitalised)	1.8%
110.	Tleyjeh, I et al(110)	Saudi Arabia	Prospective cohort	222	-	Hospitalised patients	52.5/14.0	23.0	PCR confirmed	Mixed 30.2% ICU	122 ^f	56.3%
111.	Todt, B et al(111)	Brazil	Single-centre cohort	239	-	Hospitalised patients	53.6/14.9	40.2	PCR confirmed	69.7% severe	3m post-hospital discharge	40.2%
112.	Tohamy, D et al(112)	Egypt	Retrospective comparative study with controls	100	100 randomly recruited from hospital registration system without COVID-19	Hospitalised and outpatients	55.5/6.2	43.0	PCR confirmed	25% moderate, 45% severe	3m post-hospital discharge	5.0%
113.	Townsend, L et al(113)	Republic of Ireland	Cross-sectional*	128	-	Hospitalised and non-hospitalised	49.5/15	53.9	PCR confirmed	55.5% hospitalised	72 ^f	57.8%
114.	Trunfio, M et al(114)	Italy	Cross-sectional	168	-	Hospitalised patients and outpatients	56 (43-69)	42.0	PCR confirmed	63.7% hospitalised	194 ^b	24.4%
115.	Ursini, F et al(115)	Italy	Cross-sectional	616	-	Community via social media	45/12	77.4	Positive nasopharyngeal swab	10.7% hospitalised, 1.6% ICU	6 ± 3m post-positive test	43.8%
116.	Venturelli, S et al(116)	Italy	Cohort*	767	-	Emergency Department and hospitalised patients	63/13.6	32.9	PCR confirmed	88.4% admitted 8.6% ICU	105 ^b	51.4%
117.	Walle-Hansen, M et al(117)	Norway	Cohort	106	-	Hospitalised older adult patients	74.3/n/a	43.0	PCR confirmed	26% severe	186 ^f	53.8%
118.	Weng, J et al(118)	China	Retrospective	117	-	Hospitalised patients	-	44.4	PCR confirmed	28.2% severely ill	89.5 ^e	44.4%

	Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
119.	Whitaker, M et al(119)	UK	Random community-based survey (REACT-2)	76,155	-	Community	-18+	57.3	Self-reported	0.8% admitted to hospital	84 ^a	37.7%
120.	Xiong, L et al(120)	China	Ambidirectional cohort	162	-	Hospitalised healthcare workers	36 (31-43)	77.0	'Infected with COVID-19'	100% severe, 5% ICU	153 ^f	70.4%
121.	Xiong, Q et al(121)	China	Longitudinal with controls	538	184, volunteers	Hospitalised patients	52 (41-62)	54.5	"confirmed"	5% critical, 33.5% severe	97 ^f	49.6%
122.	Yan, B et al(122)	China	Prospective observational	125	-	Mobile cabin hospital, adult males	35 (30-49)	0.0	'Diagnosed with COVID-19'	asymptomatic / mild symptoms	84 ^e	0.0%
123.	Yan, X et al(123)	China	Cohort	119	-	Hospitalised patients	53.0/12.2	59.0	PCR confirmed	24% severe	365 ^e	39.5%
124.	Yin, X et al(124)	China	Retrospective analysis	337	-	Hospitalised patients	53.5/14.8	49.5	PCR confirmed	12.8% severe, 3.6% ICU	203 ^a	55.8%
125.	Zayet, S et al(125)	France	Retrospective cohort	354	-	Hospitalised patients and outpatients	49.6/18.7	63.0	PCR confirmed	34.2% hospitalised, 5% ICU	289 ^a	35.9%
126.	Zhan, Y et al(126)	China	Prospective cohort	121	-	Hospitalised patients	49 (40-57)	58.7	PCR confirmed	15.7% severe	348 ^b	29.8%
127.	Zhang, D et al(127)	China	Retrospective comparative	122	-	Hospitalised patients	51 (31.8-61.0)	50.3	PCR confirmed	mild cases excluded, only patients with pulmonary sequelae at discharge included	92 ^f	54.9%
128.	Zhang, J et al(128)	China	Cohort*	245	-	Hospitalised patients	43 (33-54)	43.8	Nucleic acid testing	9.3% severe/critical	90 ^e	72.7%
129.	Zhang, X et al(129)	China	Retrospective multi-centre cohort	2433	-	Hospitalised patients	60 (49-68)	50.5	Laboratory confirmed	27.9% severe	364 ^f	45.0%
130.	Zhou, M et al(130)	China	Prospective cohort with controls	164	42 healthy controls – negative nucleic acid	Hospitalised patients	-	56.9	PCR and antibody test	54.6% severe	129 ^b (severe cases) 125 ^b (mild)	69.5%

Author	Country	Study design (as described by study, * if not stated)	Denominator ¹	Controls N, type	Setting	Age (years) Mean/SD Median (IQR)	% female	COVID-19 diagnostic method	Severity	Follow-up time ² Days	Finding: % with at least one symptom or pathology remaining at follow-up
				and antibody tests							

***Relevant outcome data not available for controls

References

1. Abdelrahman MM, Abd-Elrahman NM, Bakheet TM. Persistence of symptoms after improvement of acute COVID19 infection, a longitudinal study. *Journal of medical virology*. 2021;93(10):5942-6.
2. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*. 2021;594(7862):259-64.
3. Aminian A, Bena J, Pantalone KM, Burguera B. Association of obesity with postacute sequelae of COVID-19. *Diabetes, Obesity & Metabolism*. 2021;23(9):2183-8.
4. Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. *Thorax*. 2021;76:399-401.
5. Augustin M, Schommers P, Stecher M, Dewald F, Giesemann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. *The Lancet Regional Health Europe*. 2021;6:100122.
6. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ (Clinical research ed)*. 2021;372:n693.
7. Baricich A, Borg MB, Cuneo D, Cadario E, Azzolina D, Balbo PE, et al. Midterm functional sequelae and implications in rehabilitation after COVID-19: a cross-sectional study. *European journal of physical and rehabilitation medicine*. 2021;57(2):199-207.
8. Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, et al. Assessment of Cognitive Function in Patients After COVID-19 Infection. *JAMA network open*. 2021;4(10):e2130645.
9. Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC, et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. *JAMA network open*. 2021;4(1):e2036142.
10. Blanco JR, Cobos-Ceballos MJ, Navarro F, Sanjoaquin I, Arnaiz de Las Revillas F, Bernal E, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. *Clinical Microbiology & Infection*. 2021;27(6):892-6.
11. Bliddal S, Banasik K, Pedersen OB, Nissen J, Cantwell L, Schwinn M, et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. *Scientific Reports*. 2021;11(1):13153.
12. Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. Long COVID in a prospective cohort of home-isolated patients. *Nature medicine*. 2021;27(9):1607-13.
13. Boscolo-Rizzo P, Guida F, Polesel J, Marcuzzo AV, Capriotti V, D'Alessandro A, et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). *International Forum of Allergy and Rhinology*. 2021.

14. Carrillo-Garcia P, Garmendia-Prieto B, Cristofori G, Montoya IL, Hidalgo JJ, Feijoo MQ, et al. Health status in survivors older than 70 years after hospitalization with COVID-19: observational follow-up study at 3 months. *European geriatric medicine*. 2021;12(5):1091-4.
15. Caruso D, Guido G, Zerunian M, Polidori T, Lucertini E, Pucciarelli F, et al. Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up. *Radiology*. 2021;301(2):E396-E405.
16. Caspersen IH, Magnus P, Trogstad L. Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort. *European Journal of Epidemiology*. 2022;37(5):539-48.
17. Castro VM, Rosand J, Giacino JT, McCoy TH, Perlis RH. Case-control study of neuropsychiatric symptoms in electronic health records following COVID-19 hospitalization in 2 academic health systems. *Molecular Psychiatry*. 2022.
18. Chai C, Feng X, Lu M, Li S, Chen K, Wang H, et al. One-year mortality and consequences of COVID-19 in cancer patients: A cohort study. *IUBMB life*. 2021;73(10):1244-56.
19. Cirulli ET, Schiabor Barrett KM, Riffle S, Bolze A, Neveux I, Dabe S, et al. Long-term COVID-19 symptoms in a large unselected population. *medRxiv*. 2020:2020.10.07.20208702.
20. Clavario P, De Marzo V, Lotti R, Barbara C, Porcile A, Russo C, et al. Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up. *International journal of cardiology*. 2021;340:113-8.
21. Cristillo V, Pilotto A, Cotti Piccinelli S, Zoppi N, Bonzi G, Gipponi S, et al. Age and subtle cognitive impairment are associated with long-term olfactory dysfunction after COVID-19 infection. *Journal of the American Geriatrics Society*. 2021;69(10):2778-80.
22. Diaz-Fuentes G, Roa-Gomez G, Reyes O, Singhal R, Venkatram S. Coronavirus Pneumonia: Outcomes and Characteristics of Patients in an Inner-City Area after 3 Months of Infection. *Journal of clinical medicine*. 2021;10(15).
23. Domenech-Montoliu S, Puig-Barbera J, Pac-Sa MR, Vidal-Utrillas P, Latorre-Poveda M, Rio-Gonzalez AD, et al. ABO Blood Groups and the Incidence of Complications in COVID-19 Patients: A Population-Based Prospective Cohort Study. *International journal of environmental research and public health*. 2021;18(19).
24. Erol N, Alpınar A, Erol C, Sari E, Alkan K. Intriguing New Faces Of Covid-19: persisting Clinical Symptoms And Cardiac Effects in Children. *Cardiology in the young*. 2021:1-27.
25. Evans RA, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. *The Lancet Respiratory Medicine*. 2022;10(8):761-75.
26. Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. *The Lancet Respiratory Medicine*. 2021;9(11):1275-87.
27. Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, Rodriuez-Jimenez J, Palacios-Cena M, Velasco-Arribas M, et al. Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study. *Journal of Infection*. 2021;83(2):237-79.
28. Fernandez-de-Las-Penas C, Gomez-Mayordomo V, de-la-Llave-Rincon AI, Palacios-Cena M, Rodriguez-Jimenez J, Florencio LL, et al. Anxiety, depression and poor sleep quality as long-term post-COVID sequelae in previously hospitalized patients: A multicenter study. *The Journal of infection*. 2021;83(4):496-522.
29. Fernandez-de-Las-Penas C, Guijarro C, Plaza-Canteli S, Hernandez-Barrera V, Torres-Macho J. Prevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study. *Lung*. 2021;199(3):249-53.
30. Frijia-Masson J, Debray MP, Boussouar S, Khalil A, Bancal C, Motiejunaite J, et al. Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study. *Respiratory Medicine*. 2021;184:106435.
31. Froidure A, Mahsouli A, Liistro G, De Greef J, Belkhir L, Gerard L, et al. Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae. *Respiratory medicine*. 2021;181:106383.
32. Fu L, Fang Y, Luo D, Wang B, Xiao X, Hu Y, et al. Pre-hospital, in-hospital and post-hospital factors associated with sleep quality among COVID-19 survivors 6 months after hospital discharge: cross-sectional survey in five cities in China. *BJPsych open*. 2021;7(6):e191.
33. Gaber TAK, Ashish A, Unsworth A. Persistent post-covid symptoms in healthcare workers. *Occupational Medicine (Oxford)*. 2021;71(3):144-6.

34. Garcia-Abellan J, Padilla S, Fernandez-Gonzalez M, Garcia JA, Agullo V, Andreo M, et al. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. *Journal of clinical immunology*. 2021;41(7):1490-501.
35. Garratt AM, Ghanima W, Einvik G, Stavem K. Quality of life after COVID-19 without hospitalisation: Good overall, but reduced in some dimensions. *The Journal of infection*. 2021;82(5):186-230.
36. Gonzalez-Hermosillo JA, Martinez-Lopez JP, Carrillo-Lampon SA, Ruiz-Ojeda D, Herrera-Ramirez S, Amezcua-Guerra LM, et al. Post-Acute COVID-19 Symptoms, a Potential Link with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort. *Brain sciences*. 2021;11(6).
37. Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. *Radiology*. 2021;299(1):E177-E86.
38. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. *JAMA*. 2021;325(19):2015-6.
39. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet (London, England)*. 2021;397(10270):220-32.
40. Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. *Lancet (London, England)*. 2021;398(10302):747-58.
41. Jacobson KB, Rao M, Bonilla H, Subramanian A, Hack I, Madrigal M, et al. Patients With Uncomplicated Coronavirus Disease 2019 (COVID-19) Have Long-Term Persistent Symptoms and Functional Impairment Similar to Patients with Severe COVID-19: A Cautionary Tale During a Global Pandemic. *Clinical Infectious Diseases*. 2021;73(3):e826-e9.
42. Kashif A, Chaudhry M, Fayyaz T, Abdullah M, Malik A, Anwer JMA, et al. Follow-up of COVID-19 recovered patients with mild disease. *Scientific Reports*. 2021;11(1):13414.
43. Kim Y, Kim S-W, Chang H-H, Kwon KT, Bae S, Hwang S. Significance and Associated Factors of Long-Term Sequelae in Patients after Acute COVID-19 Infection in Korea. *Infection & chemotherapy*. 2021;53(3):463-76.
44. Lemhofer C, Sturm C, Loudovici-Krug D, Best N, Gutenbrunner C. The impact of Post-COVID-Syndrome on functioning - results from a community survey in patients after mild and moderate SARS-CoV-2-infections in Germany. *Journal of Occupational Medicine & Toxicology*. 2021;16(1):45.
45. Li X, Shen C, Wang L, Majumder S, Zhang D, Deen MJ, et al. Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study. *Respiratory Research*. 2021;22(1):203.
46. Liao T, Meng D, Xiong L, Wu S, Yang L, Wang S, et al. Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan. *Infectious Diseases and Therapy*. 2021.
47. Liao X, Wang Y, He Z, Yun Y, Hu M, Ma Z, et al. Three-Month Pulmonary Function and Radiological Outcomes in COVID-19 Survivors: A Longitudinal Patient Cohort Study. *Open forum infectious diseases*. 2021;8(9):ofaa540.
48. Liu Y-H, Wang Y-R, Wang Q-H, Chen Y, Chen X, Li Y, et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. *Molecular neurodegeneration*. 2021;16(1):48.
49. Liyanage-Don NA, Cornelius T, Sanchez JE, Trainor A, Moise N, Wainberg M, et al. Psychological Distress, Persistent Physical Symptoms, and Perceived Recovery After COVID-19 Illness. *Journal of General Internal Medicine*. 2021;36(8):2525-7.
50. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA network open*. 2021;4(2):e210830.
51. Lucidi D, Molinari G, Silvestri M, De Corso E, Guaraldi G, Mussini C, et al. Patient-reported olfactory recovery after SARS-CoV-2 infection: A 6-month follow-up study. *International Forum of Allergy & Rhinology*. 2021;11(8):1249-52.
52. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Pang P, et al. Long COVID in Patients With Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role? *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*. 2021;27(9):894-902.

53. Maestre-Muniz MM, Arias A, Mata-Vazquez E, Martin-Toledano M, Lopez-Larramona G, Ruiz-Chicote AM, et al. Long-Term Outcomes of Patients with Coronavirus Disease 2019 at One Year after Hospital Discharge. *Journal of clinical medicine*. 2021;10(13).
54. Martinez AE, Banderet F, Labhardt ND, Battegay M. Long-term outcome after SARS-CoV-2 infection in healthcare workers: a single centre cohort study. *Swiss medical weekly*. 2021;151:w30094.
55. Matteudi T, Luciani L, Fabre A, Minodier P, Boucekine M, Bosdure E, et al. Clinical characteristics of paediatric COVID-19 patients followed for up to 13 months. *Acta paediatrica*. 2021.
56. Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. *Brain, behavior, and immunity*. 2021;94:138-47.
57. Mechi A, Al-Khalidi A, R ALD, Al-Dujaili MN, Al-Buthabhak K, Alareedh M, et al. Long-term persistent symptoms of COVID-19 infection in patients with diabetes mellitus. *International Journal of Diabetes in Developing Countries*. 2021.
58. Mei Q, Wang F, Bryant A, Wei L, Yuan X, Li J. Mental health problems among COVID-19 survivors in Wuhan, China. *World psychiatry : official journal of the World Psychiatric Association (WPA)*. 2021;20(1):139-40.
59. Mei Q, Wang F, Yang Y, Hu G, Guo S, Zhang Q, et al. Health Issues and Immunological Assessment Related to Wuhan's COVID-19 Survivors: A Multicenter Follow-Up Study. *Frontiers in medicine*. 2021;8:617689.
60. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. *PLoS ONE [Electronic Resource]*. 2021;16(7):e0254523.
61. Milanese M, Anselmo M, Buscaglia S, Garra L, Goretti R, Parodi L, et al. COVID-19 6 months after hospital discharge: pulmonary function impairment and its heterogeneity. *ERJ open research*. 2021;7(3).
62. Millet C, Narvaneni S, Chaudhry S, Shamoon Y, Chaudhry A, Farokhian A, et al. The Long Haul: a follow up study of patients diagnosed with COVID-19 one year ago at an urban medical center in New Jersey. *Chest*. 2021;160(4):A566-A7.
63. Mohiuddin Chowdhury ATM, Karim MR, Ali MA, Islam J, Li Y, He S. Clinical Characteristics and the Long-Term Post-recovery Manifestations of the COVID-19 Patients-A Prospective Multicenter Cross-Sectional Study. *Frontiers in Medicine*. 2021;8:663670.
64. Munblit D, Bobkova P, Spiridonova E, Shikhaleva A, Gamirova A, Blyuss O, et al. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology*. 2021;51(9):1107-20.
65. Nabahati M, Ebrahimpour S, Khaleghnejad Tabari R, Mehraeen R. Post-COVID-19 pulmonary fibrosis and its predictive factors: a prospective study. *Egyptian Journal of Radiology and Nuclear Medicine*. 2021;52(1) (no pagination)(248).
66. Nehme M, Braillard O, Chappuis F, Courvoisier DS, Guessous I, CoviCare Study T. Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting. *Annals of internal medicine*. 2021;174(9):1252-60.
67. Nguyen N, Hoang VT, Lagier JC, Raoult D, Gautret P. Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. *Clinical microbiology and infection*. 2021.
68. Nunez-Fernandez M, Ramos-Hernandez C, Garcia-Rio F, Torres-Duran M, Nodar-Germinas A, Tilve-Gomez A, et al. Alterations in Respiratory Function Test Three Months after Hospitalisation for COVID-19 Pneumonia: Value of Determining Nitric Oxide Diffusion. *Journal of Clinical Medicine*. 2021;10(10):14.
69. O'Keefe JB, Minton HC, Morrow M, Johnson C, Moore MA, O'Keefe GAD, et al. Postacute Sequelae of SARS-CoV-2 Infection and Impact on Quality of Life 1-6 Months After Illness and Association With Initial Symptom Severity. *Open forum infectious diseases*. 2021;8(8):ofab352.
70. Office for National Statistics. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. In: *Statistics OfN*, editor. Office for National Statistics2021.
71. Ong SWX, Fong S-W, Young BE, Chan Y-H, Lee B, Amrun SN, et al. Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. *Open forum infectious diseases*. 2021;8(6):ofab156.


72. Orru G, Bertelloni D, Diolaiuti F, Mucci F, Di Giuseppe M, Biella M, et al. Long-COVID Syndrome? A Study on the Persistence of Neurological, Psychological and Physiological Symptoms. *Healthcare (Basel, Switzerland)*. 2021;9(5).
73. Osmanov I, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, et al. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. *The european respiratory journal*. 2021.
74. Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2021;27(10):1507-13.
75. Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, et al. Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. *medRxiv : the preprint server for health sciences*. 2021.
76. Petersen M, Kristiansen MF, Hanusson KD, Danielsen MEA, Steig B, Gaini S, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. *Clinical infectious diseases*. 2020.
77. Qin W, Chen S, Zhang Y, Dong F, Zhang Z, Hu B, et al. Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up. *European Respiratory Journal*. 2021;58(1):07.
78. Qu G, Zhen Q, Wang W, Fan S, Wu Q, Zhang C, et al. Health-related quality of life of COVID-19 patients after discharge: A multicenter follow-up study. *Journal of Clinical Nursing*. 2021;30(11-12):1742-50.
79. Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents. *JAMA*. 2021.
80. Rass V, Beer R, Schiefecker AJ, Kofler M, Lindner A, Mahlknecht P, et al. Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. *European journal of neurology*. 2021;28(10):3348-59.
81. Riestra-Ayora J, Yanes-Diaz J, Esteban-Sanchez J, Vaduva C, Molina-Quiros C, Larran-Jimenez A, et al. Long-term follow-up of olfactory and gustatory dysfunction in COVID-19: 6 months case-control study of health workers. *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery*. 2021;278(12):4831-7.
82. Righi E, Mirandola M, Mazzaferri F, Razzaboni E, Zaffagnini A, Erbogasto A, et al. Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19. *Infectious diseases and therapy*. 2021;10(3):1579-90.
83. Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, et al. Post COVID-19 in children, adolescents, and adults: results of a matched cohort study including more than 150,000 individuals with COVID-19. *medRxiv*. 2021:2021.10.21.21265133.
84. Romero-Duarte A, Rivera-Izquierdo M, Guerrero-Fernandez de Alba I, Perez-Contreras M, Fernandez-Martinez NF, Ruiz-Montero R, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. *BMC medicine*. 2021;19(1):129.
85. P S, Madhavan S, Pandurangan V. Prevalence, Pattern and Functional Outcome of Post COVID-19 Syndrome in Older Adults. *Cureus*. 2021;13(8):e17189.
86. Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. *Clinical Infectious Diseases*. 2022;74(7):1191-8.
87. Shang YF, Liu T, Yu JN, Xu XR, Zahid KR, Wei YC, et al. Half-year follow-up of patients recovering from severe COVID-19: Analysis of symptoms and their risk factors. *Journal of Internal Medicine*. 2021;290(2):444-50.
88. Sibila O, Albacar N, Perea L, Faner R, Torralba Y, Hernandez-Gonzalez F, et al. Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge. *Archivos de bronconeumologia*. 2021;57:59-61.
89. Sigfrid L, Drake TM, Pauley E, Jesudason EC, Olliaro P, Lim WS, et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. *The Lancet Regional Health Europe*. 2021;8:100186.
90. Simani L, Ramezani M, Darazam IA, Sagharichi M, Aalipour MA, Ghorbani F, et al. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. *Journal of neurovirology*. 2021.

91. Skala M, Svoboda M, Kopecky M, Kocova E, HyrsI M, Homolac M, et al. Heterogeneity of post-COVID impairment: interim analysis of a prospective study from Czechia. *Virology journal*. 2021;18(1):73.
92. Skjorten I, Ankerstjerne OAW, Trebinjac D, Bronstad E, Rasch-Halvorsen O, Einvik G, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. *European Respiratory Journal*. 2021;58(2):08.
93. Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. *The European respiratory journal*. 2021;57(4).
94. Soraas A, Bo R, Kalleberg KT, Stoer NC, Ellingjord-Dale M, Landro NI. Self-reported Memory Problems 8 Months After COVID-19 Infection. *JAMA Network Open*. 2021;4(7):e2118717.
95. Soraas A, Kalleberg KT, Dahl JA, Soraas CL, Myklebust TA, Axelsen E, et al. Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study. *PloS one*. 2021;16(8):e0256142.
96. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. *Thorax*. 2020.
97. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Prevalence and Determinants of Fatigue after COVID-19 in Non-Hospitalized Subjects: A Population-Based Study. *International journal of environmental research and public health*. 2021;18(4).
98. Stephenson T, Shafran R, De Stavola B, Rojas N, Aiano F, Amin-Chowdhury Z, et al. Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCK study). *BMJ open*. 2021;11(8):e052838.
99. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. *Nature medicine*. 2021;27(4):626-31.
100. Sykes D, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 Symptom Burden: what is Long-COVID and How Should We Manage It? *Lung*. 2021;199:113-119.
101. Taboada M, Carinena A, Moreno E, Rodriguez N, Dominguez MJ, Casal A, et al. Post-COVID-19 functional status six-months after hospitalization. *The Journal of infection*. 2021;82(4):e31-e3.
102. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *The lancet Psychiatry*. 2021;8(5):416-27.
103. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLoS medicine*. 2021;18(9):e1003773.
104. Tarsitani L, Vassalini P, Koukopoulos A, Borrazzo C, Alessi F, Di Nicolantonio C, et al. Post-traumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge. *Journal of general internal medicine*. 2021;36(6):1702-7.
105. Tawfik HM, Shaaban HM, Tawfik AM. Post-covid-19 syndrome in egyptian healthcare staff: Highlighting the carers sufferings. *Electronic Journal of General Medicine*. 2021;18(3) (em291).
106. Taylor R, Trivedi B, Patel N, Singh R, Ricketts WM, Elliott K, et al. Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia. *Clinical medicine (London, England)*. 2021.
107. Tempany M, Leonard A, Prior AR, Boran G, Reilly P, Murray C, et al. The potential impact of post-COVID symptoms in the healthcare sector. *Occupational medicine (Oxford, England)*. 2021;71(6-7):284-9.
108. Writing Committee for the CSG, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. *JAMA*. 2021;325(15):1525-34.
109. Tholin B, Ghanima W, Einvik G, Aarli B, Bronstad E, Skjonsberg OH, et al. Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis. *British Journal of Haematology*. 2021;194(3):542-6.

110. Tleyjeh IM, Saddik B, AlSwaidan N, AlAnazi A, Ramakrishnan RK, Alhazmi D, et al. Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up. *PLOS ONE*. 2021;16(12):e0260568.
111. Todt BC, Szlejf C, Duim E, Linhares AOM, Kogiso D, Varela G, et al. Clinical outcomes and quality of life of COVID-19 survivors: A follow-up of 3 months post hospital discharge. *Respiratory Medicine*. 2021;184:106453.
112. Tohamy D, Sharaf M, Abdelazeem K, Saleh MGA, Rateb MF, Soliman W, et al. Ocular Manifestations of Post-Acute COVID-19 Syndrome, Upper Egypt Early Report. *Journal of multidisciplinary healthcare*. 2021;14:1935-44.
113. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PloS one*. 2020;15(11):e0240784.
114. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, et al. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. *Viruses*. 2021;13(2).
115. Ursini F, Ciaffi J, Mancarella L, Lisi L, Brusi V, Cavallari C, et al. Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. *RMD Open*. 2021;7(3):08.
116. Venturelli S, Benatti SV, Casati M, Binda F, Zuglian G, Imeri G, et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. *Epidemiology and Infection*. 2021;149:e32.
117. Walle-Hansen MM, Ranhoff AH, Mellingsaeter M, Wang-Hansen MS, Myrstad M. Health-related quality of life, functional decline, and long-term mortality in older patients following hospitalisation due to COVID-19. *BMC geriatrics*. 2021;21(1):199.
118. Weng J, Li Y, Li J, Shen L, Zhu L, Liang Y, et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. *The Lancet Gastroenterology & Hepatology*. 2021;6(5):344-6.
119. Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. *Nature Communications*. 2022;13(1):1957.
120. Xiong L, Li Q, Cao X, Xiong H, Huang M, Yang F, et al. Dynamic changes of functional fitness, antibodies to SARS-CoV-2 and immunological indicators within 1 year after discharge in Chinese health care workers with severe COVID-19: a cohort study. *BMC Medicine*. 2021;19(1):163.
121. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clinical Microbiology and Infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2021;27(1):89-95.
122. Yan B, Song L, Guo J, Wang Y, Peng L, Li D. Association Between Clinical Characteristics and Short-Term Outcomes in Adult Male COVID-19 Patients With Mild Clinical Symptoms: A Single-Center Observational Study. *Frontiers in Medicine*. 2020;7:571396.
123. Yan X, Huang H, Wang C, Jin Z, Zhang Z, He J, et al. Follow-up study of pulmonary function among COVID-19 survivors 1 year after recovery. *The Journal of Infection*. 2021;83(3):381-412.
124. Yin X, Xi X, Min X, Feng Z, Li B, Cai W, et al. Long-term chest CT follow-up in COVID-19 Survivors: 102-361 days after onset. *Annals of Translational Medicine*. 2021;9(15):1231.
125. Zayet S, Zahra H, Royer P-Y, Tipirdamaz C, Mercier J, Gendrin V, et al. Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comte Hospital, France. *Microorganisms*. 2021;9(8).
126. Zhan Y, Zhu Y, Wang S, Jia S, Gao Y, Lu Y, et al. SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection. *Signal Transduction and Targeted Therapy*. 2021;6(1) (368).
127. Zhang D, Zhang C, Li X, Zhao J, An C, Peng C, et al. Thin-section computed tomography findings and longitudinal variations of the residual pulmonary sequelae after discharge in patients with COVID-19: a short-term follow-up study. *European Radiology*. 2021;31(9):7172-83.
128. Zhang J, Xu J, Zhou S, Wang C, Wang X, Zhang W, et al. The characteristics of 527 discharged COVID-19 patients undergoing long-term follow-up in China. *International Journal of Infectious Diseases : IJID : official publication of the International Society for Infectious Diseases*. 2021;104:685-92.

129. Zhang X, Wang F, Shen Y, Zhang X, Cen Y, Wang B, et al. Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China. *JAMA network open*. 2021;4(9):e2127403.
130. Zhou M, Xu J, Liao T, Yin Z, Yang F, Wang K, et al. Comparison of Residual Pulmonary Abnormalities 3 Months After Discharge in Patients Who Recovered From COVID-19 of Different Severity. *Frontiers in medicine*. 2021;8:682087.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only




From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Study	region	total cases	total deaths	case fatality rate (%)		
Abdelrahman et al	Other	270	61.0	(53.3, 68.4)		
Al-Aly et al (hospitalized)	N America	150	29	(18.7, 9.9)		
Al-Aly et al (non-hospitalized)	N America	113	10	(12.3, 3.1)		
Aminian et al	N America	243	1255	2839	44.2	(42.4, 46.1)
Arnold et al	Europe	90	81	110	73.6	(64.4, 81.6)
Augustin et al	Europe	131	123	442	27.8	(23.7, 32.3)
Ayoubkhani et al	Europe	154	6085	28335	21.5	(21.0, 22.0)
Bellan et al	Europe	120	128	238	53.8	(47.2, 60.2)
Blanco et al	Europe	104	52	100	52.0	(41.8, 62.1)
Bliddal et al	Europe	84	52	129	40.3	(31.8, 49.3)
Blomberg et al	Europe	183	189	312	60.6	(54.9, 66.0)
Boscolo-Rizzo et al	Europe	365	161	304	53.0	(47.2, 58.7)
COMEBAC study	Europe	127	244	478	51.0	(46.5, 55.6)
Carrillo-Garcia et al	Europe	105	100	151	66.2	(58.1, 73.7)
Caruso et al	Europe	182	91	118	77.1	(68.5, 84.3)
Caspersen et al	Europe	350	28	170	16.5	(11.2, 22.9)
Castro et al	N America	128	721	6619	10.9	(10.2, 11.7)
Chai et al	China	378	156	546	28.6	(24.8, 32.6)
Ciurilli et al	N America	90	18	122	14.8	(9.0, 22.3)
Clavario et al	Europe	121	160	200	80.0	(73.8, 85.3)
Cristillo et al	Europe	196	50	101	49.5	(39.4, 59.6)
Diaz-Fuentes et al	N America	84	88	111	79.3	(70.5, 86.4)
Domenech-Montoliu et al	Europe	213	258	483	53.4	(48.9, 57.9)
Erol et al	Other	170	45	121	37.2	(28.6, 46.4)
Fernandez-de-Las-Penas et al	Europe	227	930	1142	81.4	(79.1, 83.7)
Froidure et al	Europe	95	73	107	68.2	(58.5, 76.9)
Garcia-Abellan et al	Europe	182	28	116	24.1	(16.7, 33.0)
Gonzalez-Hermosillo et al	Other	105	119	130	91.5	(85.4, 95.7)
Han et al	China	175	71	114	62.3	(52.7, 71.2)
Havervall et al	Europe	122	69	323	21.4	(17.0, 26.2)
Huang et al	China	186	1265	1655	76.4	(74.3, 78.5)
Jacobson et al	N America	119	79	118	66.9	(57.7, 75.3)
Kashif et al	Other	105	101	242	41.7	(35.5, 48.2)
Li et al	China	120	173	289	59.9	(54.0, 65.6)
Liao et al	China	409	113	303	37.3	(31.8, 43.0)
Liao et al	China	104	122	142	85.9	(79.1, 91.2)
Logue et al	N America	169	53	177	30.0	(23.3, 37.3)
Lucidi et al	Europe	186	40	110	36.4	(27.4, 46.1)
Lui et al	China	96	41	204	20.1	(14.8, 26.3)
Martinez et al	Europe	168	69	260	26.5	(21.3, 32.3)
Matteudi et al	Europe	180	23	137	16.8	(11.0, 24.1)
Mazza et al	Europe	104	81	226	35.8	(29.6, 42.5)
Mei et al	China	158	976	3677	26.5	(25.1, 28.0)
Menges et al	Europe	219	106	431	24.6	(20.6, 28.9)
Milanesi et al	Europe	196	64	135	47.4	(38.8, 56.2)
Millet et al	N America	365	83	173	48.0	(40.3, 55.7)
Mohiuddin et al	Other	161	67	313	21.4	(17.0, 26.4)
Munblit et al	Europe	232	1534	2649	57.9	(56.0, 59.8)
Nabahati et al	Other	104	90	173	52.0	(44.3, 59.7)
Nehme et al	Europe	243	160	410	39.0	(34.3, 43.9)
Nunez-Fernandez et al	Europe	98	58	200	29.0	(22.8, 35.8)
ONS study August 2021	Europe	84	2501	21374	11.7	(11.3, 12.1)
Ong et al	Other	104	13	175	7.4	(4.0, 12.4)
Osmanov et al	Europe	270	126	519	24.3	(20.6, 28.2)
PHOSP-COVID study	Europe	174	797	861	92.6	(90.6, 94.2)
Peghin et al	Europe	191	241	599	40.2	(36.3, 44.3)
Peluso et al	N America	112	89	143	62.2	(53.8, 70.2)
Petersen et al	Europe	125	95	180	52.8	(45.2, 60.2)
Qin et al	China	105	87	647	13.4	(10.9, 16.3)
Qu et al	China	105	176	540	32.6	(28.7, 36.7)
Radika et al	Europe	84	4	109	3.7	(1.0, 9.1)
Rass et al	Europe	90	82	135	60.7	(52.0, 69.0)
Riestra-Ayora et al	Europe	182	52	195	26.7	(20.6, 33.5)
Righi et al	Europe	84	83	421	19.7	(16.0, 23.8)
Roessler et al (adults)	Europe	91	13396	145184	9.2	(9.1, 9.4)
Roessler et al (children)	Europe	91	734	11950	6.1	(5.7, 6.6)
Romero-Duarte et al	Europe	196	509	797	63.9	(60.4, 67.2)
Sathyamurthy et al	Other	104	66	279	23.7	(18.8, 29.1)
SeeBle et al	Europe	147	107	146	73.3	(65.3, 80.3)
Shang et al	China	196	441	796	55.4	(51.9, 58.9)
Sibila et al	Europe	116	98	172	57.0	(49.2, 64.5)
Sigfrid et al	Europe	222	305	327	93.3	(90.0, 95.7)
Simani et al	Other	197	12	120	10.0	(5.3, 16.8)
Skala et al	Europe	91	56	102	54.9	(44.7, 64.8)
Skjorten et al	Europe	105	59	126	46.8	(37.9, 55.9)
Sonnweber et al	Europe	103	73	133	54.9	(46.0, 63.5)
Soraas et al	Europe	126	380	676	56.2	(52.4, 60.0)
Stephenson et al	Europe	104	2038	3065	66.5	(64.8, 68.2)
Sudre et al	Other	84	108	4182	2.6	(2.1, 3.1)
Sykes et al	Europe	127	75	127	59.1	(50.0, 67.7)
Taquet et al	N America	90	100007	273618	36.5	(36.4, 36.7)
Tarstani et al	Europe	105	34	115	29.6	(21.4, 38.8)
Tawfik et al	Other	91	40	120	33.3	(25.0, 42.5)
Taylor et al	Europe	126	261	545	47.9	(43.6, 52.2)
Tleyjeh et al	Other	136	125	222	56.3	(49.5, 62.9)
Todt et al	Other	105	96	239	40.2	(33.9, 46.7)
Tohamy et al	Other	105	5	100	5.0	(1.6, 11.3)
Townsend et al	Europe	86	74	128	57.8	(48.8, 66.5)
Venturelli et al	Europe	105	394	767	51.4	(47.8, 55.0)
Walle-Hansen et al	Europe	200	57	106	53.8	(43.8, 63.5)
Weng et al	China	104	52	117	44.4	(35.3, 53.9)
Xiong et al	China	111	267	538	49.6	(45.3, 53.9)
Xiong et al	China	167	114	162	70.4	(62.7, 77.3)
Yan et al	China	98	0	125	0.0	(0.0, 2.9)
Yan et al	China	379	47	119	39.5	(30.7, 48.9)
Yin et al	China	203	176	316	55.7	(50.0, 61.3)
Zayef et al	Europe	289	127	354	35.9	(30.9, 41.1)
Zhan et al	China	348	36	121	29.8	(21.8, 38.7)
Zhang et al	China	378	1095	2433	45.0	(43.0, 47.0)
Zhang et al	China	105	178	245	72.7	(66.6, 78.1)
Zhang et al	China	106	67	122	54.9	(45.7, 63.9)
Zhou et al	China	127	114	164	69.5	(61.9, 76.5)
cross-sectional						
Baricich et al	Europe	139	66	204	32.4	(26.0, 39.2)
Becker et al	N America	231	178	740	24.1	(21.0, 27.3)
Fija-Masson et al	Europe	91	103	137	75.2	(67.1, 82.2)
Fu et al	China	196	20	199	10.1	(6.2, 15.1)
Gaber et al	Europe	122	61	138	44.2	(35.8, 52.9)
Kim et al	Other	195	591	900	65.7	(62.5, 68.8)
Lemhofer et al	Europe	91	226	365	61.9	(56.7, 66.9)
Liu et al	China	196	373	1301	28.7	(26.2, 31.2)
Liyange-Don et al	N America	113	99	153	64.7	(56.6, 72.3)
Maestre-Muniz et al	Europe	379	309	543	56.9	(52.6, 61.1)
Mechi et al	Other	274	92	112	82.1	(73.8, 88.7)
Nguyen et al	Europe	213	30	125	24.0	(16.8, 32.5)
O'Keefe et al	N America	119	79	198	39.9	(33.0, 47.1)
Otru et al	Europe	91	113	152	74.3	(66.6, 81.1)
Slavem et al	Europe	117	185	451	41.0	(36.4, 45.7)
Taboada et al	Europe	189	67	183	47.5	(40.1, 55.0)
Tempany et al	Europe	84	116	217	53.5	(46.6, 60.2)
Trunfo et al	Europe	194	41	168	24.4	(18.1, 31.6)
Ursini et al	Europe	182	270	616	43.8	(39.9, 47.9)
Whitaker et al	Europe	84	28713	76155	37.7	(37.4, 38.0)



Author	Study Design	Setting	n	Days	Days	Days	Days
Bellan et al	hospitalised	multiple domains	128	238	53.8	(47.2, 60.2)	
Bianco et al	hospitalised	single domain	52	100	62.0	(41.8, 62.1)	
Frija-Masson et al	hospitalised	single domain	107	172	62.0	(52.7, 71.2)	
Froidure et al	hospitalised	single domain	95	73	107	68.2	(58.5, 76.9)
Han et al	hospitalised	single domain	175	71	114	62.3	(52.7, 71.2)
Li et al	.	single domain	120	173	289	59.9	(54.0, 65.6)
Liao et al	healthcare workers	single domain	409	113	303	37.3	(31.8, 43.0)
Liao et al	hospitalised	single domain	104	122	142	85.9	(79.1, 91.2)
Milanesa et al	hospitalised	multiple domains	196	64	135	47.4	(38.8, 56.2)
Nabahati et al	hospitalised	single domain	104	90	173	52.0	(44.3, 59.7)
Nunez-Fernandez et al	hospitalised	single domain	98	58	200	29.0	(22.8, 35.8)
Qin et al	hospitalised	single domain	105	87	647	13.4	(10.9, 16.3)
Sibila et al	hospitalised	single domain	116	98	172	57.0	(49.2, 64.5)
Sonnweber et al	community	single domain	103	73	133	54.9	(46.0, 63.5)
Tohamy et al	outpatients	single domain	105	5	100	5.0	(1.6, 11.3)
Yan et al	hospitalised	single domain	379	47	119	39.5	(30.7, 48.9)
Yin et al	hospitalised	single domain	203	176	316	55.7	(50.0, 61.3)
Zhang et al	hospitalised	single domain	105	178	245	72.7	(66.6, 78.1)
Zhang et al	hospitalised	single domain	106	67	122	54.9	(45.7, 63.9)
Zhou et al	hospitalised	single domain	127	114	164	69.5	(61.9, 76.5)

symptoms & function discovered at follow-up							
Abdelrahman et al	outpatients	multiple domains	270	105	172	61.0	(53.3, 68.4)
Arnold et al	hospitalised	multiple domains	90	81	110	73.6	(64.4, 81.6)
Augustin et al	community	multiple domains	131	123	442	27.8	(23.7, 32.3)
Baricich et al	hospitalised	single domain	139	66	204	32.4	(26.0, 39.2)
Becker et al	outpatients	single domain	231	178	740	24.1	(21.0, 27.3)
Bliddal et al	community	multiple domains	84	52	129	40.3	(31.8, 49.3)
Blomberg et al	outpatients	multiple domains	183	189	312	60.6	(54.9, 66.0)
Boscolo-Rizzo et al	community	multiple domains	365	161	304	53.0	(47.2, 58.7)
COMEBAC study	hospitalised	multiple domains	127	244	478	51.0	(46.5, 55.6)
Carrillo-Garcia et al	hospitalised	multiple domains	105	100	151	66.2	(58.1, 73.7)
Caruso et al	hospitalised	multiple domains	182	91	118	77.1	(68.5, 84.3)
Chai et al	hospitalised	multiple domains	378	156	546	28.6	(24.8, 32.6)
Cirulli et al	community	multiple domains	90	18	122	14.8	(9.0, 22.3)
Clavario et al	hospitalised	single domain	121	160	200	80.0	(73.8, 85.3)
Cristillo et al	hospitalised	single domain	196	50	101	49.5	(39.4, 59.6)
Diaz-Fuentes et al	hospitalised	multiple domains	84	88	111	79.3	(70.5, 86.4)
Domenech-Montoliu et al	community	multiple domains	213	258	483	53.4	(48.9, 57.9)
Erol et al	hospitalised	multiple domains	170	45	121	37.2	(28.6, 46.4)
Fernandez-de-Las-Penas et al	hospitalised	single domain	227	930	1142	81.4	(79.1, 83.7)
Fu et al	hospitalised	single domain	196	20	199	10.1	(6.2, 15.1)
Gaber et al	healthcare workers	multiple domains	122	61	138	44.2	(35.8, 52.9)
Garcia-Abellan et al	hospitalised	multiple domains	182	28	116	24.1	(16.7, 33.0)
Gonzalez-Hermosillo et al	hospitalised	multiple domains	105	119	130	91.5	(85.4, 95.7)
Havervall et al	healthcare workers	multiple domains	122	69	323	21.4	(17.0, 26.2)
Huang et al	hospitalised	multiple domains	186	1265	1655	76.4	(74.3, 78.5)
Jacobson et al	outpatients	multiple domains	119	79	118	66.9	(57.7, 75.3)
Kashif et al	.	single domain	105	101	242	41.7	(35.5, 48.2)
Kim et al	outpatients	multiple domains	195	591	900	65.7	(62.5, 68.8)
Lemhofer et al	community	multiple domains	91	226	365	61.9	(56.7, 66.9)
Liu et al	hospitalised	single domain	196	373	1301	28.7	(26.2, 31.2)
Liyanage-Don et al	hospitalised	multiple domains	113	99	153	64.7	(56.6, 72.3)
Logue et al	outpatients	multiple domains	169	53	177	30.0	(23.3, 37.3)
Lucidi et al	.	single domain	186	40	110	36.4	(27.4, 46.1)
Lui et al	hospitalised	multiple domains	96	41	204	20.1	(14.8, 26.3)
Maestre-Muniz et al	hospitalised	multiple domains	379	309	543	56.9	(52.6, 61.1)
Martinez et al	healthcare workers	multiple domains	168	69	260	26.5	(21.3, 32.3)
Matteudi et al	outpatients	multiple domains	180	23	137	16.8	(11.0, 24.1)
Mazza et al	hospitalised	single domain	104	81	226	35.8	(29.6, 42.5)
Mechi et al	outpatients	multiple domains	274	92	112	82.1	(73.8, 88.7)
Mei et al	hospitalised	multiple domains	158	976	3677	26.5	(25.1, 28.0)
Menges et al	community	multiple domains	219	106	431	24.6	(20.6, 28.9)
Millet et al	hospitalised	multiple domains	365	83	173	48.0	(40.3, 55.7)
Mohiuddin et al	outpatients	multiple domains	161	67	313	21.4	(17.0, 26.4)
Munblit et al	hospitalised	multiple domains	232	1534	2649	57.9	(56.0, 59.8)
Nehme et al	.	multiple domains	243	160	410	39.0	(34.3, 43.9)
Nguyen et al	hospitalised	single domain	213	30	125	24.0	(16.8, 32.5)
O'Keefe et al	outpatients	multiple domains	119	79	198	39.9	(33.0, 47.1)
ONS study August 2021	community	multiple domains	84	2501	21374	11.7	(11.3, 12.1)
Ong et al	hospitalised	multiple domains	104	13	175	7.4	(4.0, 12.4)
Orru et al	social media	single domain	91	113	152	74.3	(66.6, 81.1)
Osmanov et al	hospitalised	multiple domains	270	126	519	24.3	(20.6, 28.2)
PHOSP-COVID study	hospitalised	multiple domains	174	797	861	92.6	(90.6, 94.2)
Peghin et al	outpatients	multiple domains	191	241	599	40.2	(36.3, 44.3)
Peluso et al	social media	single domain	112	89	143	62.2	(53.8, 70.2)
Petersen et al	community	multiple domains	125	95	180	52.8	(45.2, 60.2)
Qu et al	hospitalised	single domain	105	176	540	32.6	(28.7, 36.7)
Radtke et al	community	multiple domains	84	4	109	3.7	(1.0, 9.1)
Rass et al	hospitalised	single domain	90	82	135	60.7	(52.0, 69.0)
Riestra-Ayora et al	healthcare workers	single domain	182	52	195	26.7	(20.6, 33.5)
Righi et al	hospitalised	multiple domains	84	83	421	19.7	(16.0, 23.8)
Romero-Duarte et al	hospitalised	multiple domains	196	509	797	63.9	(60.4, 67.2)
Sathyanurthy et al	hospitalised	multiple domains	104	66	279	23.7	(18.8, 29.1)
Seesle et al	outpatients	multiple domains	147	107	146	73.3	(65.3, 80.3)
Shang et al	hospitalised	multiple domains	196	441	796	55.4	(51.9, 58.9)
Sigfrid et al	hospitalised	multiple domains	222	305	327	93.3	(90.0, 95.7)
Simani et al	hospitalised	single domain	197	12	120	10.0	(5.3, 16.8)
Skala et al	outpatients	multiple domains	91	56	102	54.9	(44.7, 64.8)
Skjorten et al	hospitalised	single domain	105	59	126	46.8	(37.9, 55.9)
Soraas et al	community	multiple domains	126	380	676	56.2	(52.4, 60.0)
Stavem et al	community	multiple domains	117	185	451	41.0	(36.4, 45.7)
Stephenson et al	community	multiple domains	104	2038	3065	66.5	(64.8, 68.2)
Sudre et al	community	multiple domains	84	108	4182	2.6	(2.1, 3.1)
Sykes et al	hospitalised	single domain	127	75	127	59.1	(50.0, 67.7)
Taboada et al	hospitalised	multiple domains	189	87	183	47.5	(40.1, 55.0)
Tarstani et al	hospitalised	single domain	105	34	115	29.6	(21.4, 38.8)
Tawfik et al	healthcare workers	single domain	91	40	120	33.3	(25.0, 42.5)
Taylor et al	hospitalised	single domain	126	261	545	47.9	(43.6, 52.2)
Tempany et al	healthcare workers	multiple domains	84	116	217	53.5	(46.6, 60.2)
Teyjeh et al	hospitalised	multiple domains	136	125	222	56.3	(49.5, 62.9)
Todd et al	hospitalised	single domain	105	96	239	40.2	(33.9, 46.7)
Townsend et al	outpatients	multiple domains	86	74	128	57.8	(48.8, 66.5)
Turfinio et al	hospitalised	multiple domains	194	41	168	24.4	(18.1, 31.6)
Ursini et al	social media	single domain	182	270	616	43.8	(39.9, 47.9)
Venturelli et al	outpatients	multiple domains	105	394	767	51.4	(47.8, 55.0)
Walle-Hansen et al	hospitalised	single domain	200	57	106	53.8	(43.8, 63.5)
Weng et al	hospitalised	single domain	104	52	117	44.4	(35.3, 53.9)
Whitaker et al	community	multiple domains	84	28713	76155	37.7	(37.4, 38.0)
Xiong et al	healthcare workers	single domain	167	114	162	70.4	(62.7, 77.3)
Xiong et al	hospitalised	single domain	111	267	538	49.6	(45.3, 53.9)
Yan et al	hospitalised	multiple domains	98	0	125	0.0	(0.0, 2.9)
Zayet et al	hospitalised	multiple domains	289	127	354	35.9	(30.9, 41.1)
Zhan et al	hospitalised	multiple domains	348	36	121	29.8	(21.8, 38.7)
Zhang et al	hospitalised	multiple domains	378	1095	2433	45.0	(43.0, 47.0)

outcomes from health record linkage							
Al-Aly et al (hospitalized)	hospitalised	single domain	150	1091	11800	9.2	(8.7, 9.8)
Al-Aly et al (non-hospitalized)	community	single domain	126	1718	60255	2.9	(2.7, 3.0)
Aminian et al	outpatients	multiple domains	243	1255	2839	44.2	(42.4, 46.1)
Ayoubkhani et al	hospitalised	single domain	154	6085	28335	21.5	(21.0, 22.0)
Caspersen et al	community	single domain	350	28	170	16.5	(11.2, 22.9)
Castro et al	hospitalised	single domain	128	721	6619	10.9	(10.2, 11.7)
Roessler et al (adults)	community	multiple domains	91	13396	145184	9.2	(9.1, 9.4)
Roessler et al (children)	community	multiple domains	91	734	11950	6.1	(5.7, 6.6)
Taquet et al	community	multiple domains	90	100007	273618	36.5	(36.4, 36.7)

